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Abstract 
Background: Tuberculosis (TB) is an infectious disease caused by a bacterial infection. In 
Norway, screening immigrants for and treating latent TB infection (LTBI) is done to prevent 
active TB. LTBI, unlike active TB, does not cause symptoms but may cause progression 
(reactivation) to active TB later. The current screening strategy is a two-step strategy 
screening with tuberculin skin test (TST) and interferon gamma release assays (IGRA) when 
the TST is positive on immigrants from countries with a high prevalence of TB. A new 
screening strategy for LTBI where only IGRA is used will likely be introduced. Two other 
options, no LTBI-screening or screening only those with risk factors for reactivation may be 
considered as well because of potentially reduced costs. Before the new strategy is 
implemented the options for screening should be evaluated. 
Aim: The study was designed to compare the cost-effectiveness of four different screening 
strategies for LTBI in immigrants in Norway using cost-effectiveness analysis (CEA).The 
strategies were: (1) No screening for LTBI, (2) screening only people with risk factors for 
reactivation with IGRA, (3) screening all immigrants with TST and IGRA, and (4) screening 
all immigrants with IGRA only.  
Methods: A combined decision tree and Markov-model was developed where the outcome 
was avoided cases of active TB. The model was partially probabilistic. Costs were considered 
from a health budget perspective. Both deterministic and probabilistic sensitivity analyses 
(PSA) were conducted. Expected value of perfect information was estimated to indicate the 
potential gains from further research.  
Results: The results of the model indicate that the strategy combining TST and IGRA is not 
cost-effective at any willingness-to-pay (WTP) threshold. The three other screening-strategies 
were cost-effective at different thresholds of WTP. Screening all immigrants with IGRA was 
cost-effective at a WTP above NOK 222 000. Screening only immigrants with risk factors 
was cost-effective between a WTP of NOK 24 000 and NOK 222 000, while no LTBI-
screening was cost-effective when WTP is below NOK 24 000.  
Conclusion:  Going from the two-step model to IGRA would be cost-effective if the WTP is 
above NOK 222 000 per avoided case of active TB. No LTBI-screening or screening only 
immigrants with risk factors should be considered if the WTP is below NOK 222 000.  
V 
 
Acknowledgements 
I am thankful to the people at the Norwegian Institute of Public Health for giving me the 
opportunity to write about tuberculosis, for giving me an office space and for helping me 
through the process. I have received help from many people there, and have learned a lot 
during my stay. Some have been especially involved, and in no particular order I would like 
to thank Trude Margrete Arnesen, Brita Askeland Winje, Siri Schøyen Seterelv and Margot 
Einöder-Moreno.  
In addition to those at the Institute, many people in different parts of the health system have 
been really helpful in helping me estimate costs. Thank you. 
For commenting on the thesis I would like to thank Maja, Ørjan and Margot.  
One person has also given me great moral support. Thank you, Maja. 
Last, but not least, I appreciate the great help I have received from my supervisor, Associate 
Professor Eline Aas at the Department of Health Management and Health Economics.  
My supervisor was Associate Professor Eline Aas at the University of Oslo. My co-
supervisors were Trude Margrete Arnesen, MD, PhD, MPH and Brita Askeland Winje, PhD, 
MPH at the Norwegian Institute of Public Health. 
 
 
Fredrik Salvesen Haukaas 
May, 2014. 
VI 
 
Table of contents 
1 Introduction ........................................................................................................................ 1 
2 Background ........................................................................................................................ 3 
2.1 Tuberculosis................................................................................................................. 3 
2.2 Diagnosis ..................................................................................................................... 4 
2.3 Screening ..................................................................................................................... 6 
2.4 Treatment ..................................................................................................................... 7 
2.4.1 Active TB ............................................................................................................. 7 
2.4.2 LTBI ..................................................................................................................... 8 
2.4.3 Side effects ........................................................................................................... 9 
3 Health economic evaluation ............................................................................................. 10 
3.1 Types of analyses and perspectives ........................................................................... 10 
3.2 Decision analytic modelling ...................................................................................... 12 
3.3 Presentation of results ................................................................................................ 14 
3.3.1 Incremental cost-effectiveness ratio ................................................................... 14 
3.3.2 Uncertainty ......................................................................................................... 17 
3.3.3 Expected value of perfect information ............................................................... 18 
4 Research question ............................................................................................................. 20 
5 Methods ............................................................................................................................ 21 
5.1 The model .................................................................................................................. 21 
5.1.1 Overview ............................................................................................................ 21 
5.1.2 Decision tree ....................................................................................................... 22 
5.1.3 Markov model .................................................................................................... 24 
5.2 Literature review ........................................................................................................ 25 
5.3 Outcome and probabilities ......................................................................................... 26 
5.3.1 Outcome ............................................................................................................. 26 
5.3.2 Probabilities ........................................................................................................ 26 
5.4 Costs .......................................................................................................................... 30 
5.4.1 Screening ............................................................................................................ 30 
5.4.2 Treatment ........................................................................................................... 31 
5.5 Important simplifications and summary of the model ............................................... 35 
6 Results .............................................................................................................................. 37 
VII 
 
6.1 Costs and health consequences .................................................................................. 37 
6.2 Sensitivity analysis .................................................................................................... 39 
6.2.1 Deterministic sensitivity analysis ....................................................................... 39 
6.2.2 Probabilistic sensitivity analysis ........................................................................ 42 
7 Discussion ........................................................................................................................ 45 
7.1 General ....................................................................................................................... 45 
7.2 Strengths and limitations ........................................................................................... 45 
7.2.1 Probabilities ........................................................................................................ 45 
7.2.2 Costs ................................................................................................................... 49 
7.2.3 Other issues in the model ................................................................................... 50 
7.3 Findings of other studies............................................................................................ 52 
8 Conclusion and policy implications ................................................................................. 54 
References ................................................................................................................................ 55 
Appendix I: Decision trees ....................................................................................................... 60 
Appendix II: Costs ................................................................................................................... 63 
Appendix III: Cost-effectiveness plane .................................................................................... 68 
Appendix IV: Alternative display of results ............................................................................ 69 
Appendix V: Scenario analysis ................................................................................................ 70 
Appendix VI: One-way sensitivity analysis for probabilities .................................................. 71 
Appendix VII: One-way sensitivity analysis for costs ............................................................. 74 
 
 
 
 
 
 
 
 
 
 
 
VIII 
 
List of tables 
 
 
Table 1 Input probabilities, alpha, beta, distribution and source(s) used in the decision tree . 27 
Table 2 Input probabilities and source(s) used in the Markov model ...................................... 29 
Table 3 Costs associated with screening .................................................................................. 30 
Table 4 Costs associated with treatment .................................................................................. 32 
Table 5 Summary of the cots-effectiveness analysis ............................................................... 36 
Table 6 Deterministic results per screened individual. Results with extendedly dominated 
(ED) strategy included in square brackets ................................................................................ 37 
Table 7 Table showing deterministic results for a cohort of 16 000. Results with extendedly 
dominated (ED) strategy included in square brackets .............................................................. 38 
Table 8 One-way sensitivity analysis for some chosen parameters ......................................... 40 
Table 9 Result of a scenario analysis with annual reactivation probabilities lowered and 0.2 
additional active cases per reactivated case. Results with extendedly dominated (ED) included 
in square brackets. .................................................................................................................... 41 
Table I Table showing detailed costs ....................................................................................... 63 
Table II Results with a cohort of 10 000 .................................................................................. 69 
Table III Results when active cases are discounted at the same rate as costs (4%) ................. 69 
Table IV Results without costs of treatment of active TB ....................................................... 70 
Table V Results when reactivation probabilities reduced in all groups (0.0025 and 0.0045 
annual probability) ................................................................................................................... 70 
Table VI Results with secondary cases (0.2 per reactivated case) ........................................... 70 
Table VII Results when probability of group with risk factors being put on treatment is 
increased to 0.9 ......................................................................................................................... 70 
Table VIII Several one-way analyses for probabilities, with and without extendedly 
dominated (ED) strategies. ....................................................................................................... 71 
Table IX Several one-way analyses for costs, with and without the extendedly dominated 
(ED) strategies included. .......................................................................................................... 74 
  
IX 
 
List of figures 
 
Figure 1 Cases of tuberculosis from 1978 to 2012  reported to the Norwegian Surveillance 
System for Communicable Diseases (MSIS) (Arnesen et al., 2013) ......................................... 1 
Figure 2 A cost-effectiveness plane (Hounton & Newlands, 2012) ........................................ 16 
Figure 3 Illustration of the model ............................................................................................. 22 
Figure 4 Cost-effectiveness plane showing the results of 5000 iterations. Results per screened 
immigrant. ................................................................................................................................ 38 
Figure 5 Cost-effectiveness acceptability curve ....................................................................... 43 
Figure 6 Cost-effectiveness acceptability frontier and expected value of perfect information 
curve ......................................................................................................................................... 43 
Figure 7 Expected value of perfect parameter information for costs and probabilities per 
screened individual. .................................................................................................................. 44 
Figure I and II Decision trees for No LTBI-screening and IGRA risk .................................... 60 
Figure III Decision tree for TST+IGRA .................................................................................. 61 
Figure IV Decision tree for IGRA ............................................................................................ 62 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Acronyms 
BCG Bacillus Calmette-Guérin 
CBA Cost-benefit analysis 
CEA Cost-effectiveness analysis 
CEAC Cost-effectiveness acceptability curve 
CEAF Cost-effectiveness acceptability frontier 
CUA Cost-utility analysis 
DOT Directly observed therapy 
DRG Diagnosis related group 
EVPI Expected value of perfect information 
EVPPI Expected value of perfect parameter 
information 
FFS Fee for service 
HIV Human immunodeficiency virus 
ICER Incremental cost-effectiveness ratio 
IGRA Interferon gamma release assay 
LTBI Latent tuberculosis infection 
MDR-TB Multi-drug-resistant tuberculosis 
MSIS Norwegian Surveillance System for 
Communicable Diseases 
NIPH Norwegian Institute of Public Health 
NPV Negative predictive value 
OUS Oslo University Hospital 
PPD Purified protein derivative 
PPV Positive predictive value 
PSA Probabilistic sensitivity analysis 
QALY Quality Adjusted Life Years 
QFT-GIT QuantiFERON-TB Gold In-Tube 
RCT Randomized controlled trial 
TB Tuberculosis 
TST Tuberculin skin test 
VAT Value added tax 
WHO World Health Organization 
WTP Willingness-to-pay 
XDR-TB Extensively drug-resistant tuberculosis 
 
1 
 
1 Introduction 
Tuberculosis (TB) is an infectious disease caused by the bacteria Mycobacterium tuberculosis 
(Merck, 2009). Even if it is a preventable and treatable disease there were around 8.6 million 
new TB cases and 1.3 million deaths worldwide in 2012 (WHO, 2013). It is the second 
leading cause of death from infectious disease after the human immunodeficiency virus (HIV) 
(WHO, 2013).  
In Norway there have been between 300 and 400 cases of tuberculosis per year the last 
decade. In Figure 1 we see that the number of cases reported to the National Institute of 
Public Health (NIPH) declined from 1978 to the mid-nineties. At that time the number of 
reported cases started to increase again, even when the reported cases in the Norwegian-born 
population kept on decreasing. The reason is that more TB-cases in Norway now occur in the 
foreign born population. 
 
Figure 1 Cases of tuberculosis from 1978 to 2012  reported to the Norwegian Surveillance System for 
Communicable Diseases (MSIS) (Arnesen et al., 2013) 
Early detection and treatment of tuberculosis is not only important to stop transmission to 
other individuals, but it can also help to halt the increase of cases that are resistant to 
medication (NIPH, 2013), which require longer and more expensive treatment. One 
possibility is to screen for and treat latent TB infection (LTBI). LTBI occurs when the initial 
infection is halted and does not turn into active disease. Because a person with LTBI is at risk 
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of developing active TB later (reactivation), treating LTBI can reduce the amount of TB cases 
developed in the future.  
In Norway screening for and treating both active TB and LTBI is currently being done on 
immigrants from countries with a high prevalence of TB. LTBI-screening is done with a two-
step strategy, where a tuberculin skin test (TST) is taken first, and an interferon gamma 
release assay-test (IGRA) is taken if the TST is positive. A new strategy in which immigrants 
are tested only with IGRA will likely be introduced in the near future. Before the new strategy 
is implemented the options for screening should be evaluated. 
It could be interesting to consider strategies which a priori seem as though they may reduce 
costs. Because resources are scarce screening involves a tradeoff. Resources spent on LTBI 
cannot be used on other health interventions, so it is important to ensure that the resources are 
used in a way that ensures as much benefit as possible. Possible strategies that could reduce 
costs are screening only immigrants at high risk for reactivation and not screening for LTBI at 
all. Intuitively, screening only immigrants at risk for reactivation could decrease costs without 
substantially increasing the amount of cases of active TB. Not screening for LTBI could also 
be done. In that case it would be necessary to treat more reactivated cases in the future. 
Whether this saves costs or not is difficult to know a priori. 
This study was designed to identify which screening strategies for LTBI would be cost-
effective in Norway, by comparing the four different strategies mentioned above: (1) No 
screening for LTBI, (2) screening only people with risk factors for reactivation with IGRA, 
(3) screening with TST and IGRA, and (4) screening all immigrants with IGRA only. The 
comparison was done using cost-effectiveness analysis (CEA). A benefit of the study will also 
be that it provides rough estimates of the costs of screening and treating latent and active 
tuberculosis in Norway. 
Including the introduction, the thesis is divided into eight chapters. The second chapter 
provides information about TB and screening. The third chapter provides some theoretical 
information about health economic evaluation. The fourth chapter states the research 
question. The fifth chapter describes the methods used in this study. The sixth chapter shows 
the results of the model and sensitivity analyses. The seventh chapter consists of a discussion 
of the results and strengths and limitations of the study. The eighth and final chapter provides 
the conclusion.  
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2 Background 
2.1 Tuberculosis 
There are different types of TB. TB can be pulmonary, laryngeal, urogenital and renal. It is 
also possible to have tuberculous meningitis and tuberculosis in the lymph nodes, but TB in 
the lungs (pulmonary TB) is the most common type (WHO, 2013). About two thirds of 
tuberculosis cases reported in Norway in 2012 were cases of pulmonary TB (Arnesen et al., 
2013). 
The symptoms of pulmonary TB can be prolonged cough with sputum, fever, night sweats, 
and feeling unwell. The main symptom is probably cough with sputum (NIPH, 2013). One 
problem with this type of symptoms is that they are unspecific and it can be difficult to 
suspect TB on the basis of them. It is also possible to have no symptoms, at least in early 
phases of the disease (Merck, 2009; NIPH, 2013). These factors can contribute to delay in 
seeking help and can lead to transmission of the bacteria to other people (WHO, 2014).  The 
symptoms of TB in other organs than the lungs (extra-pulmonary TB) vary depending on 
where the TB is located, and these symptoms will not be pursued further here. 
The main route of infection by TB is by inhaling airborne droplets expelled from people with 
pulmonary TB. Although other rare ways of becoming infected exist as well (Merck, 2009), 
pulmonary TB is generally considered the only infectious type of TB. To be able to transmit 
the disease, a sufficient amount of bacteria is required in the sputum. When the bacteria are 
inhaled by another person, they are transmitted down to the alveolar surfaces of the lungs 
where they breed and further spread (Merck, 2009).  
Whenever the droplets are expelled out into a room and reach a surface it is hard to make 
them airborne again as inhalable particles. Because of that, once the droplets reach a surface 
their ability to spread the infection is weakened (Merck, 2009). The risk of infection may 
increase with recurring contacts with an infected and untreated individual, or by staying in the 
same poorly ventilated room for a longer period (Merck, 2009). WHO estimates that 
approximately 10-15 people get infected for every person ill of TB (WHO, 2014), but once 
treatment is started the contagiousness of the disease decreases rapidly (Merck, 2009).  
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In most people the initial infection is stopped or eliminated by host defenses, which means the 
infection will remain latent (latent tuberculosis infection, LTBI) (Pai et al., 2014). This 
happens in about 95% of TB-infections (Merck, 2009), so in most cases people do not 
develop active TB (pulmonary or extra-pulmonary) on the onset. People with LTBI are 
asymptomatic and cannot infect others (Pai et al., 2014), but the bacilli may reactivate and 
cause active TB later. About 1/3 of the world’s population is estimated to be infected with 
TB, and most of these are cases of LTBI (Merck, 2009). 1/3 of the world’s population then 
has the potential for reactivation. 
The probability that the infection will cause reactivation varies from sub-group to sub-group, 
and is a debated number (Pareek et al., 2011). Some groups are considered especially at risk 
for reactivation, such as the immunosuppressed (young children and HIV-infected) and 
people recently infected. HIV-infected also have a higher mortality rate once they develop 
active TB (WHO, 2013).  
One subject that has been in focus lately is the fact that the prevalence of multidrug-resistant 
TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) has been on the increase 
(Merck, 2009). MDR-TB is defined as TB that is resistant to the first-line drugs isoniazid and 
rifampicin. XDR-TB is defined as resistance to both isoniazid and rifampicin, and in addition 
other second-line drugs (NIPH, 2013). These types of TB are harder and more expensive to 
treat, and the treatment of TB has been focused on getting people to complete treatment to 
avoid development of MDR bacteria.  
2.2 Diagnosis 
Active TB is often suspected on the basis of symptoms, and further inquiries are made with 
chest x-rays (Merck, 2009). Changes in the findings on chest x-rays are considered the most 
important indication of pulmonary TB, but it is not possible to diagnose TB with chest x-rays 
alone (NIPH, 2013). The gold standard for diagnosing active TB is by culturing a sputum 
sample from the patient (CDC, 2013a). Another way of diagnosing tuberculosis is by direct 
microscopy of the sputum sample, although this is less sensitive than the culture (NIPH, 
2013). Sensitivity is defined as the test’s ability to give a positive result, given that the patient 
actually has the disease. Direct microscopy requires a large amount of bacteria per milliliter 
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sputum in order to be interpreted as positive, and if the direct microscopy is regarded as 
positive this indicates that the disease is more likely to be infectious (NIPH, 2013).  
When it comes to latent TB, little is known and there is no gold standard for diagnosis. 
However, there are two tests that help in the immunological diagnosis of LTBI: The 
tuberculin skin test (TST, also called the Mantoux-test) and interferon-gamma release assays 
(IGRA).  
The TST is conducted by injecting purified protein derivative (PPD, derived from tuberculin) 
under the skin of the forearm. If the patient has been exposed to the bacteria earlier a cell-
mediated immunity to these antigens should occur, and a hypersensitivity reaction should 
cause an induration on the skin. The size of the induration should be measured 48-72 hours 
after the injection (CDC, 2013a). This requires the patient to have two contacts with health 
services: one for injecting PPD, and one for reading the test. Different cut-offs are used for 
concluding that the test is positive, and in Norway the cut-off is ≥ 6 mm (NIPH, 2013).  
According to Pai et al. (2014) several issues should ideally be considered when interpreting a 
TST as positive. Aside from the size of the induration, the pretest probability of infection and 
the risk of disease if the person was infected should also be considered. Pai et al. mention two 
important causes of false positive TST results: Infection with non-tuberculous mycobacterium 
and prior bacillus Calmette-Guérin (BCG) vaccination. False positives as a result of BCG 
happen because the patient has been exposed to similar antigens earlier. The specificity of the 
test is lowered in those circumstances. Here specificity is the test’s ability to produce a 
negative result given that the patient does not have LTBI. The degree to which BCG 
influences the specificity depends partly on when the BCG was given and partly on how 
many times it was given. For instance, if it was given at birth and not repeated the influence 
would be minimal (Pai et al., 2014).  
There are two types of IGRA tests. The QuantiFERON-TB Gold In-Tube (QFT-GIT) and the 
T-Spot TB test (CDC, 2013a). These are blood tests that test the cell-mediated immune 
response (Pai et al., 2014). The proteins used in IGRA-tests are more specific for 
mycobacterium tuberculosis than the PPD used in TST, and are not shared with the strains in 
the BCG-vaccine. This makes the IGRA-test more specific in these cases (Nahid, Pai, & 
Hopewell, 2006). One benefit of the IGRA is that it is not as subjected to interpreter-bias as 
the TST and may not be as time-consuming since it only requires one contact with the patient. 
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The result of an IGRA-test can be available 24-48 hours after taking the test, but 
unfortunately the results may sometimes for differing reasons have low reproducibility (Pai et 
al., 2014).  
Neither TSTs nor IGRAs  can distinguish between LTBI and active TB, meaning that a 
positive result could mean both types (Delogu, Sali, & Fadda, 2013).  Diagnosis of LTBI is 
based on obtaining a positive IGRA or TST and then eliminating the possibility of active 
disease with other tests such as chest x-ray and culture (NIPH, 2013). Since there is no gold 
standard, assessing the sensitivity and specificity of these tests needs to be done through other 
methods.  One method to determine specificity is to use the tests on people who are assumed 
to have a very low risk of having LTBI. To determine sensitivity, active TB has sometimes 
been used as a surrogate for LTBI.  One would then regard the test’s ability to turn positive 
when a person has active TB as the sensitivity for LTBI. 
Normally, positive predictive value (PPV) and negative predictive value (NPV) are defined as 
the probability that a person has the disease given a positive test, and the probability that the 
person does not have the disease given a negative test respectively (Hunink et al., 2001, p. 
134). A recent meta-analysis by Diel, Loddenkemper and Nienhaus. (2012) that studied IGRA 
and TST used the terms in a different way. PPV in the study meant the probability that the 
patient would progress to active TB given a positive test, and NPV meant the probability of 
not progressing given a negative test. According to the study IGRAs have a higher PPV for 
progression to active TB and a higher NPV for progression than TST (Diel et al., 2012). 
Using PPV and NPV in this sense could potentially be a fruitful way of dealing with LTBI 
until a gold-standard is found.  
2.3 Screening 
In Norway screening for both active TB and LTBI is done. According to law, three groups of 
people undergo mandatory screening for active TB and LTBI (NIPH, 2013): 
 People who come to Norway from a country with a high prevalence of tuberculosis 
and plan to stay for longer than three months, and asylum seekers and refugees. 
 People working in health care and teachers who, during the last three years, have been 
in a country with a high prevalence of tuberculosis for at least three months. 
 Other people who may have been infected or have been at risk of being infected. 
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NIPH defines high prevalence as a prevalence of 40 per 100 000 population. For LTBI, only 
people below the age of 35 are screened. This is because the risk of side effects is greater in 
older people and that younger people have a higher risk of reactivation.  
Asylum-seekers and refugees undergo screening at Refstad, an asylum-center, where they 
take TST and chest x-ray and are referred to specialist health care (or primary health care in 
some instances) to take IGRA if TST is positive. Immigrants below the age of 15 do not take 
chest x-rays. Other immigrants (students, workers etc.) from high prevalence countries first 
take TST in primary health care and chest x-rays in specialist health care. They then take an 
IGRA-test if TST is positive. A new strategy is probably going to be introduced where TST is 
abandoned and screening is conducted using only IGRA. The IGRA-test will be then 
performed at Refstad instead of TST.  
The Norwegian Institute of Public Health (NIPH) guidelines stipulate that if an individual is 
IGRA-positive and active TB has been excluded, the person should be put on preventive 
treatment if there is a sufficient risk that the bacilli may reactivate. Examples of risk-factors in 
the Norwegian guidelines are HIV-infection, immunosuppressant treatment, abnormal chest 
x-rays, being recently infected and being below 17 years of age, or an even higher risk below 
5 years of age. The guidelines also say that the risk of side effects should be considered before 
starting treatment, unless there is a very high risk of reactivation (NIPH, 2013). 
It is not known to what extent people are actually given treatment based on these risk factors, 
and some risk factors may not always be known. For instance, immigrants are offered an 
HIV-test, but not all of them take it.  
2.4  Treatment 
2.4.1 Active TB 
Active TB should always be treated in order to get rid of the disease and stop further 
spreading (NIPH, 2013). The recommended medications for active TB are isoniazid, 
rifampicin, pyrazinamide and ethambutol so long as the TB is drug sensitive. The length of 
treatment recommended in Norway is 6 months, with one dose of medication taken every day. 
First there is an intensive phase were all these drugs are used, then after about 2 months it is 
recommended to reduce the medication to just isoniazid and rifampicin (NIPH, 2013). These 
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principles are recommended for both pulmonary TB and extra-pulmonary TB, but there are 
some exceptions such as tuberculous meningitis which requires longer treatment. The type of 
medications used MDR-TB or XDR-TB may vary and be different from these, but this is not 
considered further here because it is not part of the analysis. 
Pulmonary TB requires hospitalization the first few weeks in order to prevent the infection 
from spreading. During this stay the patient is given medication and kept under watch. Before 
release from hospital or at the beginning of treatment for extra-pulmonary TB, a meeting is 
held where the patient, doctor, community nurse, tuberculosis coordinator and a nurse from 
the home services often participate. At this meeting the treatment is planned, and there is 
room for individual adjustments to the patient (NIPH, 2013).  
When the patient is no longer in hospital, directly observed therapy (DOT) is normally used. 
This is when a nurse comes home to the patient every day to ensure that the patient takes the 
medication. In addition the patient is required to go to follow-up consultations with a doctor 
where new blood tests, chest x-rays and sputum samples are collected. This is to monitor the 
development of the disease and to watch for side effects. Before treatment is ended the patient 
is required to produce two negative cultures (NIPH, 2013). 
During hospitalization, follow-up consultations and other contacts with the health system an 
interpreter is often required because the patients often do not understand Norwegian or 
English to a sufficient degree. This is paid for by the health care system (NIPH, 2013). 
2.4.2 LTBI 
LTBI is treated to avoid reactivation, and the treatment is often called preventive treatment or 
chemoprophylaxis. Guidelines made by the NIPH use a point system to determine whether 
someone should be put on preventive treatment or not. These points are given for risk factors 
associated with reactivation, some of which were mentioned in the previous section. Some 
risk factors are given more points than others, and if these exceed a certain level preventive 
treatment is recommended (NIPH, 2013). 
The current recommendation for treating LTBI in Norway is to take rifampicin and isoniazid 
in combination for 3 months (3RH). Another commonly used regimen has been 6 or 9 months 
of isoniazid only (6H or 9H). The medication is taken once per day. Treatment meetings are 
also used for LTBI, and among the issues considered here is the need for DOT. For LTBI 
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whether the patient receives DOT or not depends on among other things if the patient 
understands why he/she is given treatment, and if the patient shows lacking motivation for 
taking the medication (NIPH, 2013). As with the treatment for active TB, treatment for LTBI 
requires the patient to have follow-up consultations with a doctor, although these are fewer 
than for active TB.  
2.4.3 Side effects 
Unfortunately, the medication for treating both active TB and LTBI can cause side effects. 
Isoniazid may cause clinical hepatitis (0.1%) and peripheral neuropathy (<0.2%) (CDC, 
2013b). Rifampicin may among other things cause hepatotoxicity, nausea and skin reactions 
(CDC, 2013b). Side effects have important ramifications for treatment in several ways. 
Patients with LTBI do not feel ill, and may believe that the risk of developing active TB is 
low. This may cause them to drop out of or not accept treatment. Side effects are also one 
reason why people are not always put on treatment even though they are suspected of having 
LTBI. For both active and latent TB dropping out of the treatment may contribute to the 
development of resistant bacteria.  
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3 Health economic evaluation 
3.1 Types of analyses and perspectives 
Because resources are scarce, they need to be allocated in a way that ensures as much benefit 
as possible is produced from their use. This is also true for the health sector. Economic 
evaluation is a method used to help determine how to allocate resources (Briggs, Claxton, & 
Sculpher, 2006), and is a useful tool for improving decision-making by clearly identifying 
relevant alternatives (Drummond, Sculpher, Torrance, O'Brien, & Stoddart, 2005).  
In health economic evaluation the most commonly used methods are cost-effectiveness 
analysis (CEA), cost-utility analysis (CUA) and cost-benefit analysis (CBA). All of these 
examine both costs and consequences of health interventions, where costs are in terms of 
opportunity costs. Opportunity costs can be defined as the value of benefits of other 
alternatives that have been foregone by using resources on the alternative in question 
(Drummond et al., 2005). Common to CEA, CUA and CBA is that costs are measured in 
monetary terms. Each cost has to be identified, quantified and valuated. Identification means 
finding the costs that are relevant for the intervention of interest. The costs need to be 
quantified, which means putting a number on how much of the resource is used. Examples 
include the amount of visits to a general practitioner or how many tests are done. Valuation 
means putting a monetary value on the resource use (Drummond et al., 2005). Because people 
have a positive rate of time preference the costs also need to be adjusted for differential 
timing, which means that costs should be discounted if they occur in the future (Drummond et 
al., 2005). 
The costs that are to be included depend on the perspective of the study. In a societal 
perspective, all resource use should be considered and transfer costs should not be counted. 
By transfer costs we mean costs that do not reflect resource consumption because they are 
only a transfer from one place to another (Drummond et al., 2005). The societal perspective 
measures the impact of an intervention on the whole of society. In a health-care perspective, 
only the resources used by the health care sector are counted. Transfer costs can be counted as 
long as they are transferred out of the health-care system. In the health-care perspective 
opportunity costs can be thought of in terms of other treatments/interventions foregone 
(Drummond, Weatherly, & Ferguson, 2008). It is also possible to only look at the costs 
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incurred for the patient, which would make it a patient-perspective. The societal perspective is 
generally regarded as the preferred type of perspective in health economics. This is because 
health economics is grounded in welfare economics, which regards society’s welfare as the 
main concern (Byford & Raftery, 1998). Among the reasons why other perspectives are used 
are difficulty in obtaining data and difficulty measuring (Drummond et al., 2008).  
What differs between CEA, CUA and CBA is the way we measure outcomes. In CEA we use 
natural outcomes related to the objective of the intervention, often intermediate, such the 
reduction in blood pressure and amount of infections cured (Drummond et al., 2005). By 
intermediate it is here meant that they do not directly reflect quantity of life (mortality) and 
quality of life (morbidity), but it is also possible to use more generic outcomes, such as 
survival. 
Because many CEAs use outcomes that are specific for the disease they are of most use when 
comparing a limited set of options which use the same outcome. The downside of using this 
method is then that it does not allow for direct comparisons between programs looking at 
different diseases. Although the more generic measures can be used, they still do not capture 
both morbidity and mortality. A benefit of this approach is that it avoids the problems 
involved with valuing health states. 
In CUA quality-adjusted life-years (QALYs) are used as an outcome. QALYs measure both 
changes in mortality and morbidity, and reflect the relative desirability of different health 
states (Drummond et al., 2005). Quality of life is measured by asking respondents to elicit 
their preferences for health states in different ways. According to Drummond et al. (2005), 
three common ways of measuring are the standard gamble, time trade-off and the visual 
analogue scale. The visual analogue scale presents the respondent with a line with endpoints, 
where one end implies the highest value and the other the lowest. The respondent is then 
asked to value a disease state on this line. The standard gamble presents the respondent with a 
health state, and he/she is asked to take a gamble between perfect health and death. The 
higher the probability of death the respondent accepts, the lower the utility of that health state 
is ranked. The time trade-off asks the respondent to make a choice between two alternatives. 
Either live in health state i for time t followed by death, or be in perfect health for time x < t 
followed by death. Time x is then varied until the respondent is indifferent between the two 
alternatives, and the lower the value at which x is accepted, the worse the first health state is 
considered (Drummond et al., 2005).  
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An outcome-measure like the QALY has the benefit of trying to capture all aspects of the 
disease and can be useful for deciding amongst health programs that deal with different types 
of diseases. But there are also problems with QALYs. Among the questions raised against 
QALYs are questions about who should value the different health states, why many people 
seem unwilling to trade lifetime away and fairness issues (Nord, Daniels, & Kamlet, 2009).  
In cost-benefit analysis the outcomes are valued in monetary terms. In principle one should 
implement programs where the benefits exceed the costs, although that may depend on certain 
things such as if one is operating within a fixed budget (Drummond et al., 2005). The benefit 
of this approach is that health interventions can in principle be compared to interventions in 
other sectors of the economy, and not just to other health interventions. One problem with this 
approach is that it is hard to assign a monetary value to benefits (Drummond et al., 2008).  
There is a controversy on whether future outcomes should be discounted or not, and at what 
rate if they are to be discounted. The Norwegian Directorate of Health (2012b) recommend 
discounting both costs and outcomes at the same rate.   
3.2 Decision analytic modelling 
Decision analytic modelling is a tool used in economic evaluation. A decision analytic model 
can be defined as “a systematic quantitative approach to decision-making under uncertainty 
where at least two decision options and their respective consequences are compared and 
evaluated in terms of their expected costs and expected outcomes” (Gray, Clarke, 
Wolstenholme, & Wordsworth, 2011, p. 179). Expected costs or outcomes are simply costs or 
outcomes multiplied by the probability of them occurring. In economic evaluation decision 
analytic models use “mathematical relationships to define a series of possible consequences 
that would flow from a set of alternative options being evaluated” (Briggs et al., 2006, p. 6). 
Although randomized controlled trials (RCTs) have sometimes been used to conduct 
economic evaluations, models have certain advantages. For instance they can be used for 
extrapolating data, synthesizing evidence, indicating the need and value of further research 
and comparing alternatives that may not have been compared in an RCT (Gray et al., 2011).  
Commonly used models are the decision tree and the Markov-model. A decision tree is a 
model made up of branches, where each branch represents an event that could take place 
(Gray et al., 2011). Each branch consists of decision nodes or chance nodes. At each chance 
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node the branch is divided into further branches where each has a probability of occurring. As 
we move from left to right in the branches, a probability in a node to the right is conditional 
on all probabilities in the nodes to the left. Each branch has an associated cost and outcome 
associated with it. The expected costs and outcomes are then calculated for each branch by 
multiplying the costs and outcomes with the associated probability of moving through that 
branch.  
Markov-models are models that make it easier to follow a cohort through time than decision 
trees, since time is explicitly defined in the model (Briggs et al., 2006). The model includes 
several mutually exclusive health states, such as healthy and ill. The cohort enters the model 
and remains in the health state for at least one cycle. One cycle is a defined period of time, for 
instance one year or one month. At the end of each cycle a person in the cohort can either 
move to another health state or remain in the same. This depends on the structure of the model 
and transition probabilities. States that it is not possible to move out from are called absorbing 
states (Hunink et al., 2001). If the data is presented in rates they need to be transformed to 
probabilities using Equation [1] below (Briggs et al., 2006).  
              [1] 
Where p is the probability, r is the rate and t is the time unit.  
If the probabilities or rates are not given for the same time period as the cycle length defined 
in the Markov model, further calculations are required. For instance, if a 5-year probability of 
an event to occur is given, the probability cannot simply be divided by 5 to obtain an annual 
probability. This is because that does not take compounding into consideration (Briggs et al., 
2006). In order to calculate the annual probability, we need to go via rates by first converting 
the 5 year probability to a rate with Equation [2] (Briggs et al., 2006). 
 
   [       ]    [2] 
Second, we apply Equation [1] to convert the rate into an annual probability by using t=1.  
Costs and outcomes are assigned to each health state in the Markov model and “rewarded” to 
each member that populates the health state for a cycle. All individuals in a given health state 
have identical characteristics (Gray et al., 2011), and the Markov-model does not record what 
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other health states a person in a given health state has been through. This is often referred to 
as the ‘Markov assumption’ (Drummond et al., 2005).  
Models may be either probabilistic or deterministic. Deterministic models use point estimates 
of costs and probabilities and result in measures of costs and effects that are also point 
estimates. Probabilistic models use input parameters that are assigned a probability 
distribution in order to capture the uncertainty inherent in the parameters.  
Which probability distribution is assigned will vary dependent on what type of parameter it is. 
Briggs et al. (2006) argue that there are only a few types of distributions that can be chosen 
for each type of parameter. For probabilities they suggest the beta distribution when the data 
is binomial. The beta distribution is characterized by the two parameters α and β, where α is 
the number of events of interest and β is the complement. A Dirichlet distribution is 
recommended when the data is multinomial, and is “the multivariate generalization of the beta 
distribution” (Briggs et al., 2006, p. 88). For costs they suggest the gamma distribution. The 
gamma distribution is characterized by α and β, where α is the squared sample mean divided 
by the variance and β is the variance divided by the sample mean (Briggs et al., 2006). A 
method called Monte Carlo-simulation is then used to randomly draw values from these 
distributions many times and make many different estimates (iterations) of the costs and 
effects of the intervention (Drummond et al., 2008).  
When the structure of the model is completed and all costs, outcomes and probabilities have 
been entered into the model, we can produce estimates of expected costs and consequences. It 
is then a matter of how to present these results. 
3.3 Presentation of results 
3.3.1 Incremental cost-effectiveness ratio  
Many methods for presenting the results of an economic evaluation exist, and the most 
frequently used is probably the incremental cost-effectiveness ratio (ICER). The ICER gives 
us the difference in costs between two interventions, divided by the difference in effects. The 
formula for calculating an ICER is given in Equation [3] taken from (Gray et al., 2011).  
     
     
     
  [3] 
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Where the top part of the equation is the difference in costs between two interventions and the 
bottom part is the difference in effects. When calculating ICERs it is common to rank 
interventions from the least expensive to the most expensive, and calculate the ICER for each 
intervention compared to the one that is cheaper. The ICER will then say something about 
how much more has to be paid to achieve one more unit of effect.  
After calculating ICERs, one should exclude the dominated (which means the strategy is more 
costly and less effective) or extendedly dominated strategies. Extended dominance is when 
the ICER of a given strategy is higher than that of the next, more effective alternative 
(Drummond et al., 2005). When making decisions based on the ICER the option with the 
highest ICER below the willingness-to-pay (WTP)-threshold should be chosen (Barton, 
Briggs, & Fenwick, 2008). This is shown in Equation [4]. 
  
  
     [4] 
The equation means that interventions are deemed cost-effective if the incremental costs (  ) 
divided by the incremental benefits (    are lower than the WTP per unit of effect ( ). The 
ICERs are often illustrated on a cost-effectiveness plane, as shown in Figure 2 on the next 
page. In probabilistic models there will be several estimates of the costs and effects of each 
intervention in this cost-effectiveness plane.  
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Figure 2 A cost-effectiveness plane (Hounton & Newlands, 2012) 
The comparator is located in the origin. The other strategies can be more costly and more 
effective (north-east), less costly and more effective (south-east), less effective and more 
costly (north-west), or less effective and less costly (south-west) than the comparator. It is 
common for interventions to fall into the north-east quadrant, at least when the comparator is 
no intervention (Drummond et al., 2005). In a deterministic model we can plot point estimates 
of the interventions on the plane and draw a line between them (not illustrated in Figure 2). 
The slope of that line illustrates the ICER between the interventions (Drummond et al., 2005). 
 The WTP threshold per unit of effect is illustrated by the dotted line going through the origin 
denoted “Maximum acceptable ICER” in Figure 2, and all strategies falling below this line 
are considered cost-effective. As WTP increases, the line pivots around the origin in a 
counter-clockwise fashion. This means that if a strategy is located just above the WTP-
threshold in the north-east quadrant, it could quickly become cost-effective if the WTP-
threshold was increased. 
ICERs may be difficult to interpret if they are negative. The reason is that an intervention 
with negative effects and positive costs can result in the same ICER as an intervention with 
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negative costs and positive effects (Drummond et al., 2005). Net monetary benefit (NMB) and 
net health benefit (NHB) have become frequently used methods of presenting results that do 
not have the same problems. They only involve a re-arrangement of Equation [4]. The 
formula for NMB is given in Equation [5] (Drummond et al., 2005).  
              [5] 
Similarly, the equation can be rearranged to yield the NHB (Drummond et al., 2005): 
         
  
 
  [6] 
All strategies with a NMB > 0 or NHB > 0 are considered cost-effective because the benefits 
produced by the strategy are below the willingness to pay for these benefits. When making 
decisions based on NMB or NHB, the strategy that results in the highest number should be 
chosen. In this study only NMB will be used and NMB is what will be meant by “net benefit” 
from here on.   
3.3.2 Uncertainty 
There are different types of uncertainty inherent in modelling. According to Briggs et al. 
(2006), these can be divided into variability, parameter uncertainty, decision uncertainty and 
heterogeneity. 
Variability refers to the way that patients differ from each other. According to Briggs et al. 
(Briggs et al., 2006), it is hard to deal with the uncertainty resulting from variability and this 
will not be discussed further here. Parameter uncertainty refers to the precision of the 
estimate, for instance a probability or a mean cost entered into the model. Decision 
uncertainty refers to the fact that because parameters uncertain, there is a possibility that the 
wrong decision is made on the basis of them when entered into a model. Heterogeneity refers 
to part of variability which it is possible to explain by accounting for one or more of the 
patient’s characteristics (Briggs et al., 2006). 
Parameter uncertainty can be dealt with by applying probabilistic or deterministic sensitivity 
analysis (Briggs et al., 2006). Examples of deterministic sensitivity analysis are one-way 
analysis or scenario analysis. This involves changing the values of some of the parameters to 
see how their change influences the results. In one-way analysis we change the value of one 
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parameter at a time, while scenario analysis typically involves changing the value of multiple 
parameters to find results for a “best case” and a “worst case” scenario. It can also involve 
changing parameters to make scenarios that the analyst considers probable (Drummond et al., 
2008). In probabilistic models parameter uncertainty can also be dealt with by Monte Carlo-
simulation mentioned earlier. Using Monte Carlo-simulation to make several estimates in a 
cost-effectiveness plane can also be applied to decision uncertainty. However, it has been 
argued that cost-effectiveness acceptability curve (CEAC) must be constructed to graphically 
represent uncertainty associated with the estimated cost-effectiveness (Barton et al., 2008). 
The CEAC shows us the proportion of iterations from each strategy which are cost-effective 
for different values of the WTP-threshold. This can be interpreted as the probability that a 
strategy is cost-effective at each WTP-threshold (Barton et al., 2008).  
It has been argued that decisions should be based on expected net benefit, and the strategy 
with the highest expected net benefit should be chosen no matter what the probability is 
(Barton et al., 2008). The strategy with the highest probability of being cost-effective in the 
CEAC may not always be the one with the highest expected net benefit. This is why the cost-
effectiveness acceptability frontier (CEAF) is sometimes used (Barton et al., 2008). The 
CEAF shows the option with the highest expected net benefit for each value of the WTP-
threshold, and the associated probability of it being cost-effective. Only the strategy with the 
highest expected net benefit is shown for each level of the WTP-threshold.   
3.3.3 Expected value of perfect information 
Decisions made on the basis of existing information will be uncertain, and even though the 
evidence suggest that a given strategy has the highest net benefit, this may not be the case 
with better evidence (Briggs et al., 2006). There are costs and foregone benefits associated 
with choosing the wrong strategy. Because perfect information could eliminate the possibility 
of making the wrong decision, the expected costs of uncertainty are interpreted as the 
expected value of perfect information (EVPI) (Briggs et al., 2006). EVPI is a way to 
determine the upper limit on the value of further research to eliminate uncertainty around a 
decision for different levels of the WTP-threshold. It is the maximum amount the decision 
maker should be willing to pay for perfect information (Barton et al., 2008). 
In order to find EVPI we first we find the option with the highest expected net benefit across 
all iterations at a given WTP-threshold. This is the strategy that we would have picked at the 
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given WTP-threshold with current information. Second, we pick the strategy with the highest 
net benefit in each iteration and calculate the average for these (Barton et al., 2008). The 
reason this may differ from the one with the highest expected net benefit across all iterations, 
is that in some iterations the strategy picked may not be the one with the highest net benefit. 
We then subtract the net benefit found first from the net benefit found second. This difference 
is the EVPI for the given WTP-threshold. This process is repeated for all the WTP-thresholds 
we are interested in, and the results are plotted in a curve showing the EVPI for each WTP-
threshold. The higher the probability of making the wrong decision and the higher the costs 
associated with it, the higher the EVPI will be (Briggs et al., 2006). Because of this EVPI will 
often peak at WTP-thresholds where two strategies have similar probabilities of being cost-
effective.   
It is also possible to calculate EVPI for different parameters or groups of parameters, which is 
called expected value of perfect parameter information (EVPPI). EVPPI is defined as the 
difference between expected net benefit with current information and expected net benefit 
with perfect information, and is useful for determining in which direction further research 
should be focused (Briggs et al., 2006).  
Finding EVPPI is done in a similar way to EVPI. Following Briggs et al. (2006), to find the 
EVPPI for a given parameter at a given WTP-threshold, we first randomly draw a value from 
the parameter’s probability distribution. We then keep this value constant while we do the 
regular Monte Carlo-simulation for all parameters. We then randomly draw a new value from 
its probability distribution and repeat the process. The process should be done many times, for 
instance by randomly drawing a value from a parameter’s distribution 1000 times (inner 
loops) and doing simulations 1000 times for each value drawn (outer loops) (Briggs et al., 
2006). Each time we are done with the outer loop we record the expected net benefit for each 
strategy. In addition we record the strategy with highest expected net benefit from each outer 
loop separately. We then take the expected benefit with perfect information and subtract the 
expected net benefit for the strategy with the highest expected benefit across all loops (Briggs 
et al., 2006). This is the EVPPI at the given WTP-threshold. These results can be presented in 
a bar chart with the x-axis showing the different groups of parameters or parameters and the 
y-axis showing the EVPPI (Briggs et al., 2006).  
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4 Research question 
The question this study tried to answer was:  
Which of the following screening strategies for latent tuberculosis in immigrants are cost-
effective in a Norwegian setting: (1) No LTBI-screening, (2) screening only immigrants with 
risk factors, (3) screening with TST and IGRA, or (4) screening only with IGRA?  
An area of particular interest is whether the probable forthcoming change of strategy from 
TST and IGRA to IGRA only is a cost-effective change, and what the budget impact will be. 
To establish cost-effectiveness the goal was to look at which strategies the highest expected 
net benefit at different levels of willingness-to-pay. It was also the hope that the study would 
contribute to the knowledge about what the screening for and treatment of TB costs in 
Norway. In addition the study tried to identify the main points of uncertainty and the potential 
value of further research using expected value of perfect information. 
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5 Methods 
5.1 The model 
5.1.1 Overview 
In this chapter the model used for the CEA and then the details on input probabilities and 
costs will be described. 
A combined decision tree and Markov model was developed in Excel. The different 
procedures the immigrants go through in this model were based on NIPH’s guidelines on 
tuberculosis (NIPH, 2013), expert opinion at NIPH and personal communication with other 
people in the health system.  
The model considered 4 screening strategies for LTBI: 
1. No screening for LTBI (from here on referred to as “No screening” or “No LTBI-
screening”). The immigrants go through chest x-rays and some go through HIV 
tests, but not IGRA or TST.  
2. Screening only groups of people with risk factors for reactivation (HIV positive, 
abnormal chest x-rays) below the age of 35 from high prevalence countries for 
LTBI (from here on referred to as “IGRA risk”). The immigrants go through chest 
x-rays and some go through HIV tests, and in addition those with risk factors for 
reactivation take an IGRA test and are treated if IGRA is positive. 
3. Screening all immigrants below the age of 35 from high prevalence countries with 
TST, and then IGRA if TST is positive (from here on referred to as 
“TST+IGRA”). This is the current strategy. The immigrants go through chest x-
rays and some go through HIV tests, and in addition take a TST. If TST is positive 
they take an IGRA test and are treated if IGRA is positive. 
4. Screening all immigrants below the age of 35 from high prevalence countries with 
IGRA only (from here on referred to as “IGRA”). This is the strategy that will 
most likely be adopted in the near future. The immigrants go through chest x-rays 
and some go through HIV tests, and in addition take an IGRA test. They are 
treated if IGRA is positive. 
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From here on, when immigrants are referred to in the model, they are always below the age of 
35 and from countries with a high prevalence of TB, regardless of strategy. The model only 
looked at immigrant screening. People who are screened because they are going to work with 
children and/or in health care, and people who are screened as part of a contact investigation 
were excluded because of data limitations. 
An illustration of the model is given in Figure 3. The complete decision trees can be found in 
Appendix I. The illustration shows the decision tree part on the left side, with boxes in blue 
and yellow. Immigrants move through the decision-tree from the left and end up in one of the 
Markov states on the right, illustrated by ellipses. The Markov model is denoted with colors 
orange, red and green. The decision tree part and Markov-model part will now be presented in 
turn.  
 
 
Figure 3 Illustration of the model 
5.1.2 Decision tree 
The blue rectangles are the starting points in the model, and consist of all immigrants who are 
eligible for screening. The top blue rectangle illustrates those that have active TB upon 
entering the country. These cases are assumed to be found no matter the strategy because 
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screening for active TB is done in all strategies. They are included because they also take 
LTBI-tests, and the types will differ from strategy to strategy.  
The other blue box represents immigrants that are divided into groups depending on whether 
or not they have risk factors associated with higher probability of reactivation (high risk or 
low risk). They are illustrated in the same box because they go through identical decision 
trees. The difference between them is the Markov states they end up in. It is assumed that all 
have moved through the decision tree and into a Markov-state within a year from entering the 
model.  
After the initial grouping, those who do not have active TB move to a branch depending on 
whether they get a positive IGRA-result or not, or which result they would have gotten had 
they taken the test. Because there is no gold-standard for diagnosing LTBI, no underlying 
prevalence of LTBI is assumed. Instead the model only takes into account what the result of 
the IGRA test was, or would have been if it had been taken.  
After the initial IGRA/underlying IGRA the immigrants move through different branches 
depending on the strategy: 
 In the no LTBI-screening strategy they move directly to a Markov-state depending on 
the underlying IGRA-result, i.e. PPV high risk, PPV low risk or NPV. 
 In the IGRA risk-strategy, the group without risk factors moves directly to NPV or the 
low risk PPV state depending on the underlying IGRA result. The group with risk 
factors with a positive IGRA is considered for treatment, and if treated has a certain 
probability of completing treatment. If treatment is completed, it is assumed that there 
is no probability of reactivating and they move to the “No LTBI”-state. If treatment is 
not completed, it is assumed that they can still reactivate, and they move to the PPV-
high risk state. 
 In the TST+IGRA strategy both groups move to TST after the underlying IGRA. Here 
it is important to notice that IGRA precedes TST in the decision tree even though TST 
precedes IGRA in time in reality. Remember that for this strategy the first IGRA-
result is an underlying result, the test is only taken if TST is positive. If TST is 
negative they move directly to a Markov starting state because after a negative TST 
IGRA is not taken. Whenever a TST is positive, IGRA can be taken or not. If it is not, 
the patient is considered missing and moves to the relevant Markov-state. According 
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to NIPH’s guidelines, IGRA should always be taken if TST is positive. But sometimes 
the immigrants are not referred to the IGRA test or once they are referred they do not 
go. In reality, people could disappear if they have a negative TST as well, but this is of 
no consequence for the model as they would not get the IGRA-test anyway. Notice 
that it is possible to have both a positive and a negative TST after both an underlying a 
positive and an underlying negative IGRA. 
 The IGRA-strategy is basically the same as the IGRA-risk strategy, except that the 
group without risk factors also takes an IGRA test and is treated if IGRA is positive. 
5.1.3 Markov model 
The Markov states in this simple Markov-model are “No LTBI”, “PPV high risk”, “PPV low 
risk”, “NPV” and “Active case”. Markov states with a risk of reactivation are labelled NPV or 
PPV because the probability of the groups inside these states reactivating is based on the 
negative predictive value and positive predictive value for reactivation. PPV can be either 
high risk or low risk, which denotes if people have risk factors associated with higher 
probability of reactivation or not. The states are represented in colors representing different 
risks of reactivation. Green means that there is no probability of reactivation, orange means 
that there is a probability of reactivation and red means that they are already active cases. The 
As illustrated in Figure 3, it is only possible to stay in the initial state or move to “active 
case”, which is an absorbing state. In all strategies those that develop active TB or have active 
TB upon entry are treated. It is assumed that the treatment is started and completed in the 
same year as reactivation. All people who are in “No LTBI” stay there for the duration of the 
simulation. 
The Markov model goes on for 10 cycles before it ends, representing 10 years. People who 
have not developed TB by then are assumed to not develop it at all. Ideally we would run the 
simulation for many more cycles. However, the evidence for reactivation was considered 
insufficient to extrapolate over such a long time. No half-cycle correction was performed on 
the Markov-model, and there is no death-state or possibility to die for other reasons because 
of the time horizon.  
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5.2 Literature review 
The databases searched for data relevant for LTBI-screening, input probabilities, and 
economic evaluations: PubMed, Cochrane Library, Embase and Google Scholar. 
Searches were focused on obtaining data on the progression to active TB from LTBI, 
evidence of IGRA/TST tests, cost-effectiveness of LTBI-screening and efficacy of treatment. 
Among main keywords used were: latent tuberculosis, LTBI, screening, IGRA, 
QuantiFERON-TB, TST and Mantoux. The keywords were used in combinations with other 
keywords such as: cost-effectiveness, cost-utility, sensitivity, specificity, progression and 
reactivation. Where relevant studies were found, the reference lists of the studies were 
searched for further relevant studies. There seemed to be no randomized controlled trials 
(RCTs) relevant for my cost-effectiveness analysis. Several Norwegian studies were found 
that were used as data in the model developed for this study. There were also studies looking 
at the specificity and sensitivity of TST and IGRAs, and one of these was a meta-analysis 
which was used in the model. Systematic reviews looking at economic evaluations for 
screening for LTBI and other economic evaluations for LTBI-screening were found. These 
are discussed in the discussion-section of this paper. They were also used to get an idea of 
how to develop a model for LTBI-screening. No Norwegian studies looking at the cost-
effectiveness of LTBI-screening were found. 
The studies found that were relevant are discussed in the discussion section of this paper.  
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5.3 Outcome and probabilities  
5.3.1 Outcome 
The outcome chosen for this analysis was avoided cases of active TB. The model produces 
active cases for each strategy, and the amount of avoided cases per strategy was calculated by 
comparing the amount of active cases that occur for the given strategy with the no-screening 
strategy (where no cases are avoided). The amount of active cases per strategy is defined as 
the amount of active TB cases upon immigration plus those that develop active TB during the 
10 year simulation. Active cases were not discounted in the base analysis, although results 
with discounted active cases were also done as an alternative. 
5.3.2 Probabilities  
Decision tree 
The data used in the decision tree are given in Table 1 on the next page. The distributions 
used in the probabilistic sensitivity analysis (PSA) are also given, together with the input 
required to establish the distribution. It was not possible to obtain data to establish a 
distribution for all parameters and this model is therefore only partially probabilistic.  
All data used in the decision tree was based on Norwegian studies, data and/or expert opinion. 
The main source of data for the decision tree was a study by Winje et al. (2008). This study 
was used to establish data on the amount of IGRA-positive, active TB cases and the 
probability of getting a positive TST given different results on the IGRA test. The study was 
conducted at an asylum center in Norway. The probability of the immigrants having abnormal 
chest x-rays was obtained from a study by Harstad et al. (2009) also looking at asylum 
seekers. No data on the prevalence of active TB according to the risk group was found, so an 
identical prevalence of active TB in both groups was assumed. 
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Table 1 Input probabilities, alpha, beta, distribution and source(s) used in the decision tree 
 Probability Alpha Beta Distribution Source(s) 
Active TB 0.005 5 995 Dirichlet (Winje et al., 2008) 
Abnormal chest x-ray 0.07 323 4320 Dirichlet (Harstad et al., 2009) 
HIV-positive 0.02 130 6469 Dirichlet Expert opinion 
IGRA+ 0.29 264 648 Beta (Winje et al., 2008) 
TST+, given IGRA+ 0.88 232 32 Beta (Winje et al., 2008) 
TST+, given IGRA- 0.35 228 420 Beta (Winje et al., 2008) 
      
Probability of treatment 0.17 778 3798 Beta MSIS+estimations 
Probability of completing treatment 0.84 607 114 Beta (Olsen et al., 2013) 
Probability of  missing after TST 0.2   None Expert opinion 
Probability directly observed 
therapy in LTBI-treatment 
0.52 376 345 Beta (Olsen et al., 2013) 
Probability of taking voluntary 
HIV-test 
0.8   None Expert opinion 
 
The probability of being HIV-positive and the probability of taking a HIV test were based on 
expert opinion at the NIPH. As can be seen from the table the probability of taking an HIV-
test is 80%, which means that we will in reality not know the HIV-status of 20% of the 
immigrants. One simplification made here is then that the group without risk factors consists 
of people who have an unknown HIV-status. These 80% take the HIV-test regardless of 
strategy. 
HIV-positive and people with abnormal chest x-rays together constitute the group with risk 
factors. The group without risk factors is the complement of active TB, abnormal chest x-rays 
and HIV-positive.  
The parameter for the amount missing following a TST was estimated by expert opinion. It is 
only possible to go missing after both injection and reading, which is a simplification. 
The parameter for the probability of being treated following a positive IGRA was based on 
calculations. The amount of LTBI-treatments started is reported to the Norwegian 
Surveillance System for Communicable Diseases (MSIS), while the amount of positive 
IGRAs is not. That is why data on the proportion of IGRA-positive results from tests analyzed 
at Oslo University Hospital (OUS) were obtained and assumed to be equal for the whole 
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country. The total amount of LTBI-treatments given in Norway was then divided by the 
number of positive tests to obtain the probability of being put on treatment given a positive 
IGRA. From 2011 to 2013 there were 778 people put on preventive treatment each year on 
average. Country-wide there were 15780 IGRA-tests analyzed in 2013 (personal 
communication). According to OUS 29% of their tests are positive. If we assume that all 
preventive treatments are a result of a positive IGRA and that the proportion IGRA positive 
tests are the same for the whole country we find the probability to be about 0.17. A 
simplification made is that this probability is equal for both risk groups. The impact of this 
assumption will be investigated in the sensitivity analysis. 
There is also a probability that people will not complete treatment once treatment has been 
initiated. The probability of completing treatment and being put on DOT for LTBI is based on 
a cross-sectional study by Olsen et al. (2013). There may be several reasons why people do 
not complete treatment, for instance there may be side-effects that cause the patient to stop. It 
was assumed that people in the high risk group and low risk group have an equal probability 
of being treated and completing treatment given positive IGRAs. The assumption that people 
in the high risk group have an equal probability of being treated will be explored in the 
sensitivity analysis. 
Markov model 
In this study it was decided to use PPV and NPV for progressing to active TB based on the 
results of the IGRA as transition probabilities. The probabilities for progression were found in 
the meta-analysis by Diel et al. (2012) previously mentioned. The authors in this analysis 
made PPV estimates for people with risk factors and for groups without for both IGRA and 
TST. In the model only the PPV and NPV for IGRA were used to ensure the same amount of 
active cases would be produced in all strategies if none were treated. In addition IGRA has 
the highest values on PPV and NPV which makes it best at prediction activation.  
Risk factors in the meta-analysis were defined according to the American Thoracic 
Society/Centers for Disease Control criteria, which means HIV-infection, recent infection, 
chest x-ray findings indicating previous infection and weight  (American Thoracic Society, 
2000). The studies the meta-analysis was based on were conducted in both low-prevalence 
countries and high-prevalence countries.  The meta-analysis used data from a total of 15 
studies with 1 436 participants to establish PPV for the group with risk factors. To establish 
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the PPV in the group without risk factors data from 19 studies with a total of 5 194 
participants were used. The studies looking at people with risk factors also contained people 
without risk factors, and these same studies were used in the estimate of both PPVs. The 
meta-analysis did not separate between the two risk groups when it came to NPV, so NPV in 
this model is the same for both. There were 24 studies used for NPV estimation, with a total 
of 12 154 study participants.  
The follow-up time in the studies ranged from 1 year to 46 months, and the PPV was the 
probability of developing active disease within this time. These probabilities needed to be 
transformed to annual probabilities for the Markov-model using Equation [1] and [2]. After 
going through the studies the meta-analysis was based on, the median follow-up time for each 
study was found and used as a basis for calculating rates. t in Equation [2] was the weighted 
mean (weighted by amount of participants in the studies) of the median follow-up times. t was 
2.19 for the PPV in the high risk studies, 2.42 for the PPV in the low risk studies and 2.19 in 
the NPV studies. The rate found was then transformed to an annual transition probability with 
Equation [1], where t was set to 1 year. The results of these calculations are the numbers 
under the headline “Annual probability” in Table 2. 
Table 2 Input probabilities and source(s) used in the Markov model 
Progression 
probabilities 
Probability Follow-
up 
(years) 
Alpha Beta Distribution Annual 
probability 
Source(s) 
NPV  0.003 2.31 12 113 41 Beta 0.001 (Diel et al., 2012) 
PPV, high risk 0.068 2.19 98 1 338 Beta 0.032 (Diel et al., 2012) 
PPV, low risk 0.027 2.42 141 5 053 Beta 0.011 (Diel et al., 2012) 
Decline, 
reactivation 
probability 
0.57 10   None 0.081 (Wiker, Mustafa, 
Bjune, & Harboe, 
2010) 
 
In the model the annual probabilities of progressing to active TB declines with about 8% each 
year. The decline is based on a study by Wiker et al (2010) who calculated the 10 year 
decrease in progression rate as being 57% on average. In my model this was used to mean that 
the annual transition probabilities were reduced by 57% over 10 years, and this was 
transformed to an annual reduction with Equation [1] and [2]. In this model the decline only 
starts after the two first years. The reason for this is that this is approximately when the 
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follow-up from the meta-analysis stops and the extrapolation begins. Reduction in risk also 
seems to occur after the first few years after immigration (Pareek et al., 2011) 
5.4 Costs 
This section will give an overview of the costs of screening and treatment used in this study, 
and they can be found in Table 3 and 4 respectively. A more detailed table on the estimation 
of costs used in this model can be found in Table I in Appendix II. All costs were point 
estimates that were assigned a gamma-distribution with a standard deviation of 10% in the 
probabilistic model. They were estimated from a health budget perspective. 
The costs that needed to be identified were the costs of screening for and treatment of both 
LTBI and active TB. As mentioned these were identified with the help of NIPH’s guidelines 
and expert opinion. Unfortunately no patient-level data on costs was found. This means that 
the quantification of costs incurred were based on NIPH’s guidelines and expert opinion, and 
not on the actual use of resources.  
The valuation of costs came from different sources, including reimbursement rates (Diagnosis 
related groups (DRGs) and fee-for-service (FFS)), wage rates and market prices. Most costs 
came from reimbursement rates. FFS rates were, following guidelines by the Directorate of 
Health (2012b), multiplied by two to approximate true costs. Also following these guidelines, 
all future costs were discounted at 4%. Value-added tax (VAT) was excluded from the 
analysis, and all costs were adjusted to year 2013. 
5.4.1 Screening 
Table 3 Costs associated with screening 
 NOK Source(s)  
IGRA 386 (Forskrift om utgifter til poliklinisk helsehjelp, 2013; Statistics Norway, 
2013), expert opinion 
TST 168 (Statistics Norway, 2013), expert opinion 
HIV-test 146 (Forskrift om utgifter til poliklinisk helsehjelp, 2013; Norwegian 
Medical Association, 2013), expert opinion 
Chest x-ray 504 (Forskrift om dekning av laboratorieutgifter, 2013) 
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The relevant screening tests were the TST, IGRA, HIV-tests and chest x-rays. As mentioned 
in the section describing screening, these tests may be taken in different locations. In the 
model it was assumed that the costs are the same no matter where they are taken. 
The costs for TST were based on labor and material costs. The labor costs were based on time 
estimates made by Oslo Municipality and NIPH, and the material cost was the cost of 
tuberculin which was provided by the NIPH (NIPH, 2014). Hourly wages were based on the 
average hourly wage of nurses found at Statistics Norway (Statistics Norway, 2013).  
The costs of IGRA can be divided in two: The costs of taking the test (drawing blood), and 
the costs of analyzing the test. The cost of taking the test was the cost of labor time. The costs 
of analyzing the tests at the laboratory were based on the reimbursement rates provided by 
OUS. These rates were assumed to cover the costs of the IGRA-kit required to take the test.  
The costs of a chest x-rays were based on reimbursement rates for laboratories plus the user 
charge to patients. The user charge for patients was included because this charge is in reality 
covered by the health system. Chest x-rays are taken by everyone in the screening process, 
but in reality chest x-rays are also taken during follow-up consultations for active TB. These 
were assumed to be covered by the DRG for follow-up consultations.  
The costs of taking a HIV-test was based on the fee schedule for general practitioners, and 
reimbursement fees for laboratories for analyzing the tests.  
5.4.2 Treatment 
The relevant treatment costs are listed in Table 4 on the next page, with separate estimates for 
the three types of treatment: Pulmonary TB, extra-pulmonary TB and latent TB. The 
treatment costs can be divided into medication costs, laboratory costs and hospital costs. The 
expected costs of active TB at the bottom of the table were based on the fact that about 70% 
of active cases in Norway are pulmonary and the 30% extra-pulmonary (Arnesen et al., 2013). 
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Table 4 Costs associated with treatment 
 Pulmonary 
TB 
(NOK) 
Extra-
pulmonary 
TB 
(NOK) 
Latent 
TB  
(NOK) 
Source(s)  
Medication costs     
Intensive phase 1 467 1 913 0 (NIPH, 2013; Norwegian Medicines 
Agency, 2014b) 
Follow-up phase 1 511 1 511 0 (NIPH, 2013; Norwegian Medicines 
Agency, 2014b) 
LTBI-drug regimen   1 133 (-50% for 
partial treatment) 
(NIPH, 2013; Norwegian Medicines 
Agency, 2014b) 
Hospital costs     
Hospitalization 106 349 0 0 (NIPH, 2013; The Norwegian 
Directorate of Health, 2012a), expert 
opinion 
DOT 24 485 26 550 6 903 (-50% for 
partial treatment) 
Market price, (NIPH, 2013; Olsen et al., 
2013) About 52% get DOT for LTBI 
(Table 1) 
Follow-up 
consultations 
6 784 6 784 3 392 (NIPH, 2013; The Norwegian 
Directorate of Health, 2012a) 
Interpreter 6 752 6 752 1 688 Market price, hospital accounts, assumed 
for LTBI 
Treatment meeting 1 521 1 521 1 521 (Statistics Norway, 2013), expert opinion 
Sputum sample 106 106 106 (NIPH, 2013; Statistics Norway, 2013)  
expert opinion, 
Laboratory costs     
Blood test 192 192 192 (NIPH, 2013; Norwegian Medical 
Association, 2013) 
Laboratory analyses 2930 2930 198 (Forskrift om utgifter til poliklinisk 
helsehjelp, 2013; NIPH, 2013),expert 
opinion 
 152 097 
(*70%) 
48 259 
(*30%) 
15 133  
Costs, active TB 120 946 Costs, LTBI 15 133  
33 
 
Medication costs 
The medication costs were identified and quantified using NIPH’s guidelines, and price of the 
medication was found in the Norwegian Medicines Agency’s database (Norwegian Medicines 
Agency, 2014b).  
The treatment for active TB in this model consisted of isoniazid, rifampicin, pyrazinamide 
and ethambutol for two months (the intensive phase), and thereafter isoniazid and rifampicin 
for four months (the follow-up phase) (NIPH, 2013). The brands of drugs used were Rimstar 
for the intensive phase and Rimactazid for the follow-up phase. According to OUS a 
pulmonary TB patient normally spends about 14 days in hospital, and for pulmonary TB the 
amount of days spent in hospital was subtracted from these 6 months since DRG covers 
medication. LTBI-treatment was 3 months of rifampicin and isoniazid taken every day, and 
the brand used was Rimactazid. The amount of each type of drug taken in this model was 
calculated based on an assumption of a 70 kg person. 
All treatments for active TB used DOT in this model. For pulmonary TB the number of days 
spent in hospital was subtracted from the full days of DOT. As seen from Table 1 in the 
probabilities section, only about 52% of patients treated for LTBI receive DOT, so the full 
costs of DOT were multiplied by 0.52 here. The costs for DOT were based on the prices that 
Oslo Municipality pays to UNICARE, a private company.  
Strictly speaking the drugs used for LTBI and for active TB following hospitalization is not 
paid for by the health system, but by the National Insurance Scheme. These costs were still 
included in the analysis because they were found to fall under health care costs. 
Hospital costs 
The hospital costs in this model were the costs of hospitalization, follow-up consultations, 
interpreter, treatment plan meeting and blood tests.  
In the model the cost of the hospitalization was based on the reimbursement received by the 
hospitals through activity based funding. The relevant DRG was identified, and the costs 
calculated (The Norwegian Directorate of Health, 2012a). As mentioned the DRG is supposed 
to cover all procedures done during hospitalization, including medication and overhead costs.  
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The treatment meeting is a meeting lasting about an hour and who attends the meeting varies 
some. In this model the costs of a doctor, a tuberculosis-coordinator, a nurse and a 
representative from the home services were included. 
For extra-pulmonary TB, LTBI, and for pulmonary TB after hospitalization, the patient has to 
visit an outpatient clinic during treatment to take blood samples, sputum smears for direct 
microscopy and culture, and chest x-rays. According to NIPH guidelines this happens about 4 
times for active TB and 2 times for LTBI. The cost of a follow-up consultation was based on 
DRG, and these rates were assumed to cover the chest x-rays, sputum samples and blood tests 
taken in connection to these consultations. Therefore, the sputum samples and blood tests 
listed in Table 4 are the sputum samples and blood tests taken in addition to these follow-up 
consultations. The cost of obtaining a sputum sample outside the follow-up consultations was 
based on labor time using time estimates provided by OUS.  
Interpreter costs were based on the accounts from OUS, with an average use of 8 hours per 
patient and an average wage of NOK 844. These costs only include the average interpreter 
cost per patient with pulmonary tuberculosis, but it was assumed that the same amount of 
hours is used for extra-pulmonary TB. No data on the use of interpreter for LTBI was found, 
and was simply assumed to be considerably less at 2 hours. 
Laboratory costs 
The relevant laboratory costs were those of analyzing the blood tests and the different 
procedures conducted on the sputum samples. This includes direct microscopy, direct PCR 
(polymerase chain reaction), resistance determination, culture, and identification. All these 
costs were based on laboratory reimbursement rates, and the relevant rates were provided by 
OUS. The analysis of blood tests consists of CRP (C-Reactive protein) and 9 other tests. As 
mentioned most blood tests were assumed to be covered by DRG, except for the first test for 
every treatment. These are the ones listed in Table 4. 
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5.5 Important simplifications and summary of the model 
Creating a model involves making simplifications of reality. Some of these are summarized 
below, and are sorted depending on whether they will be discussed/explored in the sensitivity 
analysis, or if they will not. Table 5 on the next page provides a summary of the important 
features of the model.  
Simplifications that are discussed in the discussion and/or part of the sensitivity analysis: 
 No background mortality or deaths from TB. 
 Completed preventive treatment means no risk of reactivation. 
 Incomplete treatment means no effect of treatment. 
 All individuals with active TB start and complete treatment with full efficacy. 
 No active cases infect others.  
 The probability for being put on treatment is the same for both risk groups. 
 The probability of getting a positive IGRA result is the same for both risk groups. 
 The cost of treating MDR-TB is not included.  
 No side-effects from treatment 
 Results of HIV tests are known for the 80% before choosing to screen, even though in 
reality many results may not be available until a time after screening 
 All immigrants take the LTBI-test relevant for the strategy 
Other simplifications that will not be discussed further: 
 Screened individuals can only go missing after both parts of the TST, i.e. injection and 
reading. 
 All those who enter the model go through chest x-ray, although in reality children 
below the age of 15 do not. 
 Individuals with a TST resulting in an induration of over 15mm that do not get a 
positive IGRA are not considered for treatment in this model.  
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Table 5 Summary of the cots-effectiveness analysis 
Main issues  
Type of model Combined decision tree and Markov-model 
Type of economic evaluation Cost-effectiveness analysis 
Comparators 4 screening strategies:  
1. No screening for LTBI (baseline) 
2. Screening risk groups with IGRA 
3. Screening with TST+IGRA (current 
strategy) 
4. Screening with IGRA  
Perspective Health budget perspective 
Patient group Immigrants below the age of 35 from 
countries with high prevalence of TB 
Time horizon 10 years 
Outcome Avoided cases of active TB 
Unit costs Market prices, fee schedules, DRG, 
estimations, wage rates. 
VAT Excluded 
Year of costs 2013 
Discount rate (costs) 
Discount rate (effects) 
4% 
Not discounted in the base analysis 
Sensitivity analysis One-way, scenario, probabilistic 
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6 Results 
6.1 Costs and health consequences 
Table 6 shows the deterministic results per screened immigrant. Results when the extendedly 
dominated strategy is included are shown in square brackets. A cost-effectiveness plane 
resulting from 5000 iterations is shown in Figure 4 on the next page. The ICERs for the 
probabilistic results were almost identical to the ones in Table 6, and are not shown.  
Table 6 Deterministic results per screened individual. Results with extendedly dominated (ED) strategy included 
in square brackets  
  osts 
(NOK) 
Avoided 
cases 
Active cases Incremental 
costs (NOK) 
Incremental 
avoided cases 
ICER (NOK) 
No screening 4 756 0 0.0400 Baseline Baseline Baseline 
IGRA risk 4 775 0.0008 0.0392 19 0.0008 23 760 
TST+IGRA 5 303 0.0027 0.0373 ED [528] ED [0.0019] ED [272 728] 
IGRA 5 459 0.0039 0.0361 684 [155] 0.0031 [0.0012] 221 008 [134 343] 
 
In the deterministic results the expected cost per screened immigrant according to strategy 
ranged from NOK 4 756 to NOK 5 459, with the IGRA-strategy being the most costly. The 
effectiveness of the strategies increased with costs, and the amount of avoided cases was 
0.0008 with the IGRA risk strategy going up to 0.0039 with the IGRA strategy. Moving from 
the TST+IGRA-strategy to the IGRA-strategy would cost NOK 134 343 per additional 
avoided case of active TB. According to these results, TST+IGRA was not cost-effective as it 
was extendedly dominated. When removed, the resulting ICER for the IGRA-strategy was 
NOK 221 008. 
A rough estimate made by the NIPH on the amount of immigrants actually screened each year 
is 16 000, and deterministic results for a cohort of 16 000 is shown in Table 7 on the next 
page. According to these results, a cohort of 16 000 screened immigrants would cost about 
NOK 85 million over 10 years with today’s strategy. Moving to the IGRA strategy from 
TST+IGRA would cost an additional NOK 2.5 million and avoid 18.5 more cases. Moving 
from TST+IGRA to IGRA risk would reduce costs by about NOK 8.5 million, but would also 
reduce the amount of avoided cases by 31. The no LTBI-screening strategy would cost about 
NOK 300 000 less than the IGRA-risk strategy. 
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Table 7 Table showing deterministic results for a cohort of 16 000. Results with extendedly dominated (ED) 
strategy included in square brackets 
  osts 
(NOK) 
Avoided 
cases 
Active 
cases 
Incremental costs 
(NOK) 
Incremental 
avoided cases 
ICER (NOK) 
No screening 76 091 451 0 639.9 Baseline Baseline Baseline 
IGRA risk 76 395 534 12.8 627.1 304 082 12.8 23 760 
TST+IGRA 84 851 190 43.8 596.1 ED [8 455 657] ED [31.0] ED [272 728] 
IGRA 87 336 890 62.3 577.6 10 941 357 [2 485 700] 62.3 [18.5] 221 008 [134 343] 
 
 
Figure 4 Cost-effectiveness plane showing the results of 5000 iterations. Results per screened immigrant. 
The cost-effectiveness plane in Figure 4 shows the north-east quadrant and a part of the south-
east quadrant. The no screening strategy is located in the origin, which means that the costs 
and effects of the other strategies are displayed incremental relative to the no screening 
strategy. Almost all iterations were in the north-east quadrant, meaning that the strategies that 
involved screening for LTBI cost more and were (naturally) more effective than no-screening. 
It looks as if the IGRA risk-strategy in some iterations was cost-saving compared to no 
screening. The TST+IGRA and IGRA strategies in many iterations overlap, which means they 
had similar costs and effects in those cases. Still, it seems that most of the IGRA-strategy 
iterations were located to the east and north from the TST+IGRA strategy meaning it was 
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more expensive and more effective. Judging from Figure 4 it does not seem like the results 
found in Table 6 are sensitive to changes in the parameters resulting from the Monte Carlo-
simulation. 
A cost-effectiveness plane displaying the deterministic results with a cost-effectiveness 
frontier can be found in Appendix III. Since the main analysis did not include results when 
avoided cases were discounted, Table III in Appendix IV shows the results when both costs 
and avoided cases are discounted at the same rate (4%).   
6.2 Sensitivity analysis 
6.2.1 Deterministic sensitivity analysis 
Several one-way analyses and scenario analyses were performed to supplement the 
probabilistic results in Figure 4, and to get a clearer view of how the parameters influence the 
results. In all cases the TST+IGRA strategy remained extendedly dominated, but some are 
still worth commenting on. Table 8 on the next page shows some one-way analyses, of which 
not all will be commented on. One-way analyses for other parameters and more values of the 
parameters can be found in appendices VI and VII.  
It may be argued that both the costs of a TST and the treatment of active TB are higher than in 
the base estimate. TST costs may be higher because sometimes effort has to be put into 
getting people to meet up for the test. Costs of active TB may be higher because MDR-TB is 
not included in this analysis, and because the DRG costs for hospitalization may not fully 
cover the costs. Table 8 shows that if the cost of a TST increased to NOK 325 (from NOK 
168 in this study), the ICER for the IGRA-strategy became negative when TST+IGRA was 
included in the results. In this case that meant IGRA is cost-saving compared to TST+IGRA, 
because the costs were lower and avoided cases higher (not seen in Table 8). The table also 
shows that if the cost of treating active TB is increased, the ICERs for the strategies that 
involve screening for LTBI are lowered. At NOK 175 000 per treated active case, IGRA risk 
became cost saving compared to no LTBI-screening. When the costs of the IGRA-test were 
higher, all strategies that involved screening became more unattractive (higher ICERs).  
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Table 8 One-way sensitivity analysis for some chosen parameters  
Results with extendedly dominated strategies included shown in square brackets. Empty brackets mean it is 
equal. 
 Base 
estimate 
Values 
explored 
IGRA risk 
 (ICER) 
TST+IGRA 
(ICER) 
IGRA 
 (ICER) 
Probability of being missing 
after TST 
0.2 0 23 760 [] ED [237 556] 221 008  [129 077] 
   0.4 23 760 [] ED [346 314] 221 008 [135 693] 
           
Probability IGRA-positive, high 
risk group only 
0.29 0.39 12 034 [] ED [286 608] 221 008 [122 772] 
   0.59 589 [] ED [318 250] 221 008 [103 798] 
           
Probability treated, high risk 
group 
0.17 0.5 -6262 [] ED [364 662] 221 008 [89 855] 
   0.9 -13137 [] ED [599 937] 221 008 [61 201] 
           
Annual reactivation probability, 
low risk group 
0.011 0.0025 23 760 [] ED [2 706 764] 1 312 588 [507 961] 
   0.0075 23 760 [] ED [490 777] 378 344 [217 384] 
           
Annual reactivation probability, 
high risk group 
0.032 0.0045 ED [705 313] ED [237 612] 239 693 [183 857] 
   0.0200 89 989 [] ED [257 521] 221 008 [152 369] 
           
Cost, IGRA 386 300 13 624 [] ED [258 871] 195 834 [90 205] 
   500 37 194 [] ED [291 097] 254 378 [192 851] 
           
Cost, TST 168 100 23 760 [] ED [237 724] 221 008 [192 998] 
   325 23 760 [] ED [353 838] 221 008 [-1 568] 
      
Cost, active TB 120 946 75 000 62 265 [] ED [311 016] 259 319 [172 694] 
  175 000 -21 541 [] ED [227 683] 175 935 [89 223] 
      
Cost, latent TB 15 133 10 000 -4 435 [] ED [193 164] 147 053 [69 788] 
  20 000 50 489 [] ED [348 157] 291 118 [195 542] 
 
It may also be argued that the 17% estimate of the amount treated following a positive IGRA 
was too low for the group with risk factors, because these would more often be put on 
treatment because of higher risk of reactivation. It was thought that the probability 
distribution used for this parameter would not fully take this into account. As seen in Table 8 
and in Appendix VI, making the probability higher lowered the ICER of the IGRA risk-
strategy, while the ICER for IGRA strategy stayed the same. When TST+IGRA was included 
the ICER for the IGRA strategy was lowered. IGRA-risk dominated no LTBI-screening at a 
50% probability of treatment, with lower costs and higher effects (not seen in Table 8). 
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The probability of having a positive IGRA may in reality be higher for people with risk 
factors because they have a higher risk of being infected. When the probability was increased, 
the ICER fell for IGRA risk, while it stayed the same for IGRA.  When TST+IGRA was 
included, IGRA became more attractive (lower ICER) the higher the probability. 
The estimate on how many people went missing following TST was a very uncertain 
parameter, based only on expert opinion. In addition it did not have a probability distribution 
in the probabilistic model. When including TST+IGRA, the one-way sensitivity analysis 
shows that increasing the probability of being missing after TST increased the ICER of both 
TST+IGRA and IGRA. The ICER of IGRA increased because the costs of TST+IGRA were 
reduced the higher the probability became (not shown in Table 8). TST+IGRA was 
extendedly dominated at all values of the parameter. 
It is common in the tuberculosis literature to use a lower reactivation probability than is used 
in this study, often 5% to 10% probability during a person’s lifetime (often defined as 20 
years). In the one-way sensitivity analyses and scenario analyses the reactivation probability 
was varied. As with the other one-way sensitivity analyses, TST+IGRA remained extendedly 
dominated. As can be seen in Table 8, when the annual reactivation probability for the group 
with risk factors became sufficiently low, IGRA risk was extendedly dominated. Lowering 
the probability for the low risk group increased the ICERs of TST+IGRA and IGRA. 
The scenario analysis in Table 9 shows the results after the annual reactivation probability 
was set to 0.0025 for the low risk group, 0.0045 for the high risk group and 0 for the ones 
with negative IGRA. This results in about 2.5% reactivating in the low risk group and 4.5% in 
the high risk group over 10 years, which is closer to the probabilities commonly used in the 
literature (Oxlade, Pinto, Trajman, & Menzies, 2013). Since an objection to the model may be 
that it is not possible for active cases to infect others, reactivated cases also infected 0.2 other 
people with active TB. This is a number borrowed from Pareek et al. (2011).  
Table 9 Result of a scenario analysis with annual reactivation probabilities lowered and 0.2 additional active 
cases per reactivated case. Results with extendedly dominated (ED) included in square brackets. 
  osts 
(NOK) 
Avoided 
cases 
Active cases Incremental 
costs (NOK) 
Incremental 
avoided cases 
ICER (NOK) 
No screening 2 123 0 0.0141 Baseline Baseline Baseline 
IGRA risk 2 204 0.0002 0.0139 81 0.0002 413 079 
TST+IGRA 2 857 0.0009 0.0132 ED [653] ED [0.0007] ED [900 794] 
IGRA 3 091 0.0013 0.0128 887 [234] 0.0011 [0.0004] 796 387 [601 789] 
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The results show that the ICERs increase substantially, with the ICER for IGRA being about 
NOK 800 000 and the ICER of IGRA risk being about NOK 413 000. TST+IGRA remained 
extendedly dominated. One scenario with only 0.2 infected for each reactivated case, and one 
scenario with only reduced reactivation probabilities can be found in Appendix V. 
6.2.2 Probabilistic sensitivity analysis 
For the probabilistic model a cost-effectiveness acceptability curve and a cost-effectiveness 
acceptability frontier were constructed. Expected value of perfect information was calculated 
both in total and for groups of parameters. 
Figure 5 on the next page shows the CEAC, and there are two points at which the strategy 
having the highest probability of being cost-effective changes. Up to a WTP-threshold of 
NOK 24 000 the no LTBI-screening strategy has the highest probability. From there until 
NOK 222 000 it is the IGRA-risk strategy. From there and upwards it is the IGRA-strategy. 
These thresholds more or less reflect the ICERs when the extendedly dominated strategy was 
excluded from the analysis. In the deterministic sensitivity analysis some parameters were 
changed in such a way that the ICERs for some of the strategies increased. That change would 
cause the WTP-threshold needed for the given strategy to be cost-effective to increase. In the 
CEAC, TST+IGRA is not cost-effective at any threshold of WTP.  
In Figure 6 the CEAF is plotted together with the expected value of perfect information per 
screened individual. The CEAF shows us that the strategies with the highest expected net 
benefit at different WTP-thresholds are more or less consistent with which one has the highest 
probability of being cost effective shown in Figure 5. EVPI also peaks at the WTP-thresholds 
where the strategy having the highest probability of being cost-effective changes. The chance 
of picking the wrong strategy at these WTP-thresholds is relatively high, around 50%, which 
is why the EVPI is so high. The second peak has the highest EVPI, and this is where the 
optimal strategy changes from IGRA risk to IGRA. This peak shows an EVPI of about NOK 
39.4 per screened individual, which would be about NOK 630 000 if the estimate of the 
amount screened each year of 16 000 people is used.  
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Figure 5 Cost-effectiveness acceptability curve 
 
 
Figure 6 Cost-effectiveness acceptability frontier and expected value of perfect information curve 
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Figure 7 Expected value of perfect parameter information for costs and probabilities per screened individual.  
In Figure 7 the expected value of perfect parameter information is plotted for groups of 
parameters. EVPPI was esimated at the WTP-threshold that caused the highest peak in EVPI 
(NOK 222 000) with 1000 inner and 1000 outer loops per group of parameters. The results for 
the other peak, NOK 24 000, are shown in Appendix VIII.  
The results show that costs seem to be important parameters to focus further research on, 
especially the costs of IGRA and LTBI-treatment. If we assume 16 000 screened immigrants, 
the IGRA costs alone amount to an EVPPI of NOK 197 600. For the smaller peak at a WTP 
of NOK 24 000 active case costs had the highest potential gains from further reasearch 
(Appendix VIII). Here it should be mentioned again that the costs in this model were only 
point estimates which have been assigned a gamma distribution with a standard deviation of 
10% of the point estimate. The information that comes from EVPPI for costs may then be 
limited. 
It seemed as if the probabilities of having positive IGRAs and TSTs, and the probability of 
being treated and completing treatment were the most important probability parameters to 
research further. The least important group of parameters seemed to be the annual reactivation 
probabilities, although individual parameters may be low within other groups of parameters as 
well. 
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7 Discussion 
7.1  General 
The results of the model indicate that the TST+IGRA strategy is not cost-effective at any 
WTP-threshold, while the other strategies were cost-effective at different levels of the 
threshold. Ranging from least expensive and least effective to most expensive and most 
effective are no LTBI-screening, IGRA risk, TST+IGRA and IGRA. 
If this study is used as a basis for making decisions, it should be decided how high the 
willingness to pay for an avoided case of TB is. It should be taken into account that these are 
costs in addition to the screening for and treatment of active TB. The limitations of this study 
and the results of other similar studies should also be taken into consideration. Many of the 
limitations of the study were taken into account in the sensitivity analysis, but some strengths 
and limitations will be discussed in the following sections.  
7.2 Strengths and limitations 
7.2.1 Probabilities 
Sources of probabilities 
One of the strengths of this study is that the sources used for most probabilities were based on 
Norwegian data. The results may provide information that is of use in a Norwegian setting, 
and estimates that can be of use in future Norwegian studies.  
Whether the studies used as a source for many of the probabilities were representative could 
be discussed. The data from Winje et al. (2008) for instance, are based on asylum seekers 
from one relatively small time period. Immigrants who are not asylum seekers could have 
different IGRA and TST results than the ones in the study. In addition, which countries the 
immigrants originate in, and hence the prevalence of LTBI, will likely differ from time period 
to time period. Ideally RCTs or meta-analyses should be used to establish the probability of a 
positive or negative TST given a positive or a negative IGRA. Still, the results of the 
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sensitivity analysis indicate that varying these parameters did not influence which strategies 
were cost-effective. It did, however, affect the costs and effects of the strategies. 
The sources of some probabilities, such as the probability of a screened individual going 
missing after undergoing TST and the probability of being HIV-infected were only expert 
opinion. However, it was hoped that the sensitivity analysis was robust enough to show that 
these probabilities did not influence the results substantially.  
Reactivation probability and active cases 
The annual reactivation probability used in this study was high compared to many other 
studies, at 1.1% and 3.2% of the low and high risk group respectively. A systematic review by 
Oxlade, Pinto, Trajman & Menzies (2013) looked at 14 different CEAs, of which only 3 used 
an annual reactivation probability over 1%.  An often used estimate is that 5 to 10% of people 
with true LTBI reactivate during their lifetime, while my model resulted in 8.2% of the group 
without risk factors and 21.6% in the group with risk factors reactivating within 10 years. In 
addition some of those with negative tests reactivated as well. The high annual reactivation 
probabilities were probably due to two issues: 
 The reactivation probability for the group without risk factors was actually based on 
data that also contained studies where people with risk factors were included. Since in 
my study the group without risk factors actually contains young children and recently 
infected it may be argued that this weakness is not substantial. 
 Reactivation probability was extrapolated to 10 years when the follow-up was about 2 
years. The high reactivation probability used in the meta-analysis may reflect a higher 
reactivation probability the first few years. The reduction in reactivation probability 
used in this study may not have been high enough to account for the real decline. In 
another study 10% decrease in risk each decade was used (Horsburgh, 2004), but this 
probability would likely still not be enough to make the active cases in line with other 
studies.  It could be discussed whether it could be appropriate to have a follow-up of 
two years in my model instead since that is the approximate follow-up of the studies 
the meta-analysis is based on. Two years was considered to be too short given the 
nature of LTBI. 
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The result of the high reactivation probability is that the total amount of active cases of TB 
generated by this model is high compared to some other studies (Mulder, 2013; Pareek et al., 
2011). For easier comparison, Appendix IV has a table with a cohort of 10 000, which is 
sometimes used in other studies looking at LTBI-screening. As shown in the sensitivity 
analysis, the relatively high amount of active cases caused the results to be more favorable to 
the strategies that involved screening for LTBI than would otherwise be the case.  
My model used a somewhat different approach to dealing with LTBI in cost-effectiveness 
analyses than has been used earlier. Since there is no gold standard for determining whether a 
person has LTBI or not, it seems appropriate to base reactivation probability on the test’s 
ability to predict reactivation instead of assuming an underlying prevalence of LTBI. 
Depending on what one’s stance is on this issue, this approach could be considered one of the 
strengths of the study. One issue that will have to be dealt with when using this approach, 
which has not been dealt with here, is how to account for inconclusive IGRA-results.  
Risk factors 
Another strength of the study is that it takes into consideration people with risk factors. But 
several more risk factors could and arguably should have been considered. Young children, 
diabetics, people on immunosuppressant medication and people with end stage renal disease 
could all have been considered. Unfortunately the lack of time and data did not allow for it. 
Even if these risk factors were not included in the base analysis, it could be argued that the 
sensitivity analysis to some extent accounted for them since the probability of having risk 
factors was varied.  
One problem in this study is that it may not be possible to know both the risk factors before 
choosing to screen, something that at least applies for HIV. In that case screening only people 
with risk factors could be implausible. However, it is likely possible to know the results of 
chest x-rays beforehand, and chest x-rays constitute the biggest part of the group with risk 
factors. In addition, other risk factors could plausibly be substituted for the HIV positive 
status used in this paper.  
Two probability parameters in the group with risk factors should be discussed. First, as 
mentioned in the sensitivity analysis it could be argued that those who are in the group with 
risk factors are more likely to have a positive IGRA test. Ideally there should have been 
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separate estimates for the group with and the group without risk factors, but it was not 
possible to obtain data that allowed for it. For the same reason the probability of being put on 
treatment in the group with risk factors was the same as in the group without. Arguably this is 
unrealistic, and the estimate should have been higher for the risk group. The reason this may 
be unrealistic is that risk factors are supposed to be taken into account when deciding to treat 
(NIPH, 2013). As seen in the sensitivity analysis, if the probability of being treated increased 
to 50% for the high risk group, the IGRA risk strategy had less costs and more effects than no 
LTBI-screening. 50% probability of being treated in the risk group does not seem unrealistic. 
The results of EVPPI suggest that obtaining better evidence on the probability of a positive 
IGRA or TST, the probability of being treated and treatment completion could yield benefits 
when deciding on which strategy is the cost-effective one between IGRA risk and IGRA. 
Further research should be conducted to get better estimates of these parameters.  
Treatment completion 
A simplification made in the model was that all individuals partially completing treatment 
could still develop active TB, and all individuals fully completing treatment had no 
probability of reactivation. Efficacy estimates for full LTBI treatment used in other studies 
range from 65% to 90% (Oxlade et al., 2013).  My hope was that since incomplete treatment 
sometimes cures the infection and completed treatment sometimes does not, these would to 
some degree cancel each other out. Most likely however, the amount of people who are 
considered free of LTBI after treatment was overestimated in this study, probably causing the 
study to be more favorable towards the strategies that involved LTBI-screening.  
Side effects of medication could also have been included because it could influence both 
treatment completion and costs of treating side effects such as drug induced liver injury. It 
was assumed that that those who stop treatment because of side effects were already part of 
the probability of completing treatment. The costs of treating side effects were not taken into 
account, and including them would probably make the results less favorable towards the 
strategies that involved the most treatment.  
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7.2.2 Costs 
In general, the costs in this study may have been a weak link since they were only “typical 
case” estimates for the treatment costs. However, significant effort was put into estimating the 
costs as accurately as possible with help from people in many parts of the health system who 
are knowledgeable about the treatment of TB in Norway. In this section some points about the 
costs will be discussed. 
Some costs do not include overhead costs. The IGRA and TST tests for instance, were 
composed of reimbursement rates (which include overhead) and time estimates (which do 
not). Including overhead costs would increase the costs of these tests, and overhead costs may 
be important. As seen in the sensitivity analysis, the cost of the TST in particular would have 
an influence on the additional costs of adopting the IGRA strategy.  
The study did not take into account where the costs occur in the health system, something that 
could influence the results. For instance, it has been argued that replacing TST+IGRA with 
IGRA would result in freed resources at the asylum center, but an increased burden on the 
laboratories. If the freed resources at the asylum center would more than offset the increased 
costs at the laboratories, then the IGRA strategy would be viewed as more attractive. 
In general reimbursement rates were used to a large extent in this study. These are not 
accurate estimates of the true costs. As suggested from the EVPPI and sensitivity analysis, 
better estimates of costs would increase the probability of correct decisions being made.  The 
cost parameters were not based on patient level data, and because of that using EVPPI may 
not be completely justified. Still, EVPPI together with the different sensitivity analyses 
suggest that these are indeed parameters that it is important to gain more knowledge about.  
One particularly weak cost estimate is that of hospitalization based on DRG. Some have 
criticized the DRG reimbursement for not covering the full costs (personal communication). 
However, the cost estimates for treating active TB in this study were higher than estimates 
made for instance in the Netherlands and Canada (Dasgupta et al., 2000; de Vries G & R, 
2013). There are currently estimates being made on what the cost of a day in isolate costs in 
Norway, and these should be applied when making further analyses as they will probably be 
more accurate. It was hoped that the sensitivity analysis to some extent covered the 
uncertainty regarding this part of the costs. 
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Excluded costs 
The cost of treating MDR-TB was not included in the study. This type of TB requires more 
expensive medication, longer treatment, and more tests. Excluding MDR-TB may lead to an 
underestimation of the treatment costs of active TB. To some extent the possible 
underestimation was accounted for in the sensitivity analysis by increasing the costs of 
treating active TB.  
Another type of cost that was not included was patient transportation cost. Patient 
transportation costs were not included because it was difficult to obtain data. These costs are 
likely important because screening and treatment involves several trips back and forth from 
hospitals and these costs need to be covered by the health system.  If these costs were 
included they would increase the costs of all strategies that involve screening. Because of the 
extra consultation used to take the TST, the cost of this test would increase more than the 
increase for IGRA. However, the IGRA strategy results in more people getting treated and 
because of that the costs of the IGRA strategy may have increased more than that of the 
TST+IGRA strategy.   
The costs of contact tracing were not included. Every time a new active case surfaces an 
investigation has to be conducted where people are called in for screening. Costs are then 
incurred both at the NIPH and in primary health care for time used, and in addition there are 
the costs of the additional screening tests used. Including contact tracing would cause the 
IGRA strategy, which resulted in the most people treated, to be more attractive since fewer 
active cases would occur in the future. Generally the strategies that involved screening would 
have more favorable results.  
The time used by TB-coordinators was to a large extent also excluded in the study, although 
not in the treatment plan meeting. If these costs were included, it would perhaps make the 
costs of TST+IGRA and IGRA increase more than IGRA risk since those two strategies 
involve more work for the TB-coordinator because more people are screened and treated.  
7.2.3 Other issues in the model 
Because of time limitations QALYs were not used in this study. As a result it is not possible 
to compare the interventions in this study to other health-care interventions. One benefit to 
using avoided cases is that this is unambiguously the goal of a LTBI-screening program. The 
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outcome used in other cost-effectiveness analyses looking at LTBI-screening varies, and both 
QALYs and avoided cases of active TB have been used. Ideally both should have been used 
in this study. Focus of further research using this model should perhaps be focused on 
implementing QALYs. 
Discounting of effects was not done in the base study because it was decided that the amount 
of avoided cases was an interesting number in itself. Discounting would cause the number of 
avoided cases to be difficult to interpret. Not discounting effects could be considered a 
weakness since the Directorate of Health recommends discounting both costs and effects. 
However, discounting of effects was done as an alternative and those results may be referred 
to if needed. 
The comparator used in this analysis was no screening for LTBI instead of the current 
strategy. No screening was used as a comparator because avoided cases of active TB was the 
outcome, meaning that the strategies would already have to be compared to no screening on 
the effect side. It was also thought that since the strategy would likely be changed, using no 
screening as a comparator would keep the analysis more open for later use. This choice of 
comparator may make it more difficult to see the consequences of moving from TST+IGRA 
to another strategy, but effort has been put into explaining and displaying results that illustrate 
these consequences. 
The study could have been more detailed in modelling screening for active TB and treatment 
of active TB. In the model it was assumed that all people with active TB would be detected, 
and all received and accepted treatment. All of them also completed treatment, were cleared 
of TB and could no longer be infected. In addition, there was no probability that people with 
active TB could infect others in the main results. When secondary cases of active TB were 
accounted for, there was still no possibility of infecting others with LTBI or for the disease to 
spread further from those who got infected. Being more detailed in this matter would 
probably lead the strategies that involved LTBI-screening to be less attractive (higher ICERs). 
It could be discussed whether background mortality should be added to this model, but it was 
thought that it would only have a small impact since the time horizon was 10 years. Mortality 
from TB was not included either, but the number of deaths from TB is very small in a 
developed country like Norway and the impact would be small.  
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One issue that was not discussed in the model was how a change in strategy would influence 
the amount of people who take the tests. In my model it was assumed that all immigrants from 
countries with a high prevalence of TB took the screening tests. In reality, getting everyone to 
take the tests may not be as easy. One benefit of only screening with IGRA could potentially 
be that it would be easier to get the immigrants to take the test because they would know that 
the process is shorter. To some extent this was taken into account because it was possible for 
the immigrants to disappear after a TST. 
Moving from TST+IGRA to IGRA would according to this model approximately cost an 
additional NOK 2.5 million. When pharmaceutical companies in Norway apply for 
reimbursement for a drug, the Norwegian Medicines Agency has a limit of NOK 5 million in 
additional resources spent before the decision to reimburse has to go to the Ministry of Health 
and Care services (Norwegian Medicines Agency, 2014a). This is because NOK 5 million is 
considered to be a relatively low sum. If we use this as a reference when looking at these 
screening strategies then an additional NOK 2.5 million may not be considered a substantial 
amount of extra resources spent.  
7.3 Findings of other studies 
Studies that have compared similar strategies to the ones compared here have reached varying 
conclusions.  
A systematic review found that of the six studies comparing TST+IGRA to IGRA alone, four 
of them found TST+IGRA the cost-effective alternative, while the other two found IGRA 
alone to be cost-effective (Nienhaus, Schablon, Costa, & Diel, 2011). A study by Mulder et 
al. comparing no screening, TST+IGRA and IGRA found TST+IGRA to be the cost-effective 
alternative in the Netherlands (Mulder, 2013). A study by Linas, Wong, Freedberg & 
Horsburgh (2011) comparing no screening, TST-screening and IGRA-screening found IGRA 
screening to be the cost-effective strategy when screening groups of people with risk factors. 
TST only was never a relevant strategy in my study, but it is relevant to see that IGRA was 
cost-effective compared to no screening. One study concluded IGRA only to be the “cost-
effective” option when used on foreign-born population, but the study only looked for cost 
savings (Iqbal et al., 2014).  
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A study by Pareek et al. (2011) also found screening with IGRA to be cost-effective 
compared to no-screening when the incidence in the country of origin was high enough. 
When screening immigrants who came to the UK between the ages of 16 and 35 from a 
country with an incidence of TB above 250 per 100 000 population, about 30% had positive 
IGRAs. We do not know the combined incidence in countries of origin of the immigrants who 
come to Norway, but the proportion of positive IGRAs in my study was about 29% which 
should make the two comparable. In the study by Pareek et al. the ICER was £17 956 in 2010 
pounds per avoided case of TB when screening with IGRA only (Pareek et al., 2011). This 
would be about NOK 190 000 in 2013 prices.  The ICER for IGRA in my study was about 
NOK 221 000, which is a comparable number. 
It seems like other studies provide different conclusions as to which of the strategies IGRA 
and TST+IGRA are the most cost-effective, but there seems to be a general agreement that 
screening for LTBI is cost-effective. 
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8 Conclusion and policy implications 
The results of the model indicate that no screening for LTBI, screening only immigrants at 
risk for reactivation with IGRA and screening all immigrants with IGRA were cost-effective 
at different thresholds of willingness to pay (WTP). In this model screening with TST and 
IGRA was not cost-effective at any WTP-thresholds.  
Based on the results of the cost-effectiveness acceptability frontier, no screening for LTBI had 
the highest expected net benefit if WTP was NOK 24 000 or below. Between a WTP of NOK 
24 000 up to NOK 222 000 screening only immigrants with risk factors had the highest 
expected net benefit. From NOK 222 000 and up screening all immigrants with IGRA had the 
highest expected net benefit. The additional costs of adopting the IGRA-strategy from TST 
and IGRA were NOK 2.5 million for a cohort of 16 000, and would avoid 18.5 more cases 
over 10 years. The additional costs were sensitive to the cost of the TST. The model indicates 
that adopting the IGRA-risk strategy would reduce costs by NOK 8.5 million compared to 
TST+IGRA, but avoid 31 fewer cases. The no LTBI-screening strategy would cost about 
NOK 300 000 less than the IGRA-risk strategy. As shown by the cost-effectiveness 
acceptability curve there is a relatively high probability of making the wrong decision if WTP 
is around NOK 222 000 or NOK 24 000. More effort should be put into further research on 
the costs of TB. This can potentially have high returns, as can be seen from the expected 
value of perfect information and sensitivity analysis. 
The policy implications are these: Should more money be spent and increase the amount of 
avoided cases (going for the IGRA-strategy), or should less money be spent and avoid fewer 
cases by either adopting the IGRA risk-strategy or the no-screening strategy? This depends on 
the decided WTP. Either way, the results of the model indicate that the TST and IGRA 
strategy should be discarded. However, the results of some other analyses in other countries 
have shown TST and IGRA to be cost-effective and these results should also be taken into 
consideration. 
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Appendix I: Decision trees 
All decision trees were developed using Simple Decision Tree for Excel. The rightmost part of each decision tree 
indicates the Markov starting states that each branch leads to. 
 
Figure I and II Decision trees for No LTBI-screening and IGRA risk 
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Figure III Decision tree for TST+IGRA 
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Figure IV Decision tree for IGRA 
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Appendix II: Costs 
All costs taken from fee schedules or other reimbursement rates (except DRG) are multiplied by 2 to obtain a 
closer approximation to full costs. Wages found at Statistics Norway are multiplied by 1.4 to obtain an 
approximation to full cost (payroll tax, national insurance scheme).  
Table I Table showing detailed costs 
  Source(s) 
Screening costs   
IGRA   
Time for taking test (minutes) 15 Time estimate acquired from personal communication 
with Oslo Municipality and Stavanger University 
Hospital 
Wage per hour (NOK) 318.8 (Statistics Norway, 2013) 
Labor costs for taking test (NOK) 79.7 Wage per hour*time 
   
Analysis (NOK) 306 Reimbursement category 703U and 704L times 3 
(Forskrift om utgifter til poliklinisk helsehjelp, 2013). 
Categories given by Department of Microbiology, 
Oslo University Hospital.  
  Includes cost for IGRA-kit 
Total (NOK) 386   
   
TST   
   
Time (minutes) 30 Time estimate acquired by personal communication 
with Oslo Municipality and NIPH 
Wage per hour (NOK) 318.8 (Statistics Norway, 2013) 
Labor costs for taking test (NOK) 159.4 Wage per hour*time 
   
Tuberculin (NOK) 126.8 (NIPH, 2014) 
Proportion used for one test 1/15 (NIPH, 2013) 
Costs of tuberculin used each test (NOK) 8.5 Tuberculin costs*proportion used each test 
   
Total (NOK) 168   
   
Chest x-ray   
   
Reimbursement rate (NOK) 56 (Forskrift om dekning av laboratorieutgifter, 2013) 
Patient user charge (NOK) 448 (Forskrift om dekning av laboratorieutgifter, 2013) 
   
Total (NOK) 504 Chest x-rays taken during treatment are assumed to be 
covered by DRG for follow-up consultations 
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HIV-test   
   
Costs of taking test (NOK) 96 Fee schedule category 701A (Norwegian Medical 
Association, 2013) 
Analysis (NOK) 50 Reimbursement category 704N (Forskrift om utgifter 
til poliklinisk helsehjelp, 2013). Category given by 
Oslo University Hospital 
   
Total (NOK) 146   
   
Treatment costs   
Laboratory tests   
   
Sputum smear costs (NOK) 106.3 Wage rate*time used (20 minutes). Estimate by Oslo 
University Hospital 
Quantity pulmonary TB 1 Rest covered by DRG 
Quantity extra-pulmonary TB 1 Rest covered by DRG 
Quantity latent TB 1  
   
Direct microscopy (NOK) 42 Reimbursement category 704B (Forskrift om utgifter 
til poliklinisk helsehjelp, 2013). Category given by 
Levanger Hospital. 
Quantity pulmonary TB 3  
Quantity extra-pulmonary TB 3  
Quantity latent TB 1  
   
Resistance determination (NOK) 260 Reimbursement category 704Cx5 (Forskrift om 
utgifter til poliklinisk helsehjelp, 2013) Category given 
by Oslo University Hospital. 
Quantity pulmonary TB 1  
Quantity extra-pulmonary TB 1  
Quantity latent TB 0  
   
PCR (NOK) 704 Reimbursement categories 701B+701C+701G 
(Forskrift om utgifter til poliklinisk helsehjelp, 2013) 
Categories given by Oslo University Hospital. 
Quantity pulmonary TB 2  
Quantity extra-pulmonary TB 2  
Quantity latent TB 0  
   
Culture (NOK) 52 Reimbursement category 704C (Forskrift om utgifter 
til poliklinisk helsehjelp, 2013). Category given by 
Oslo University Hospital. 
Quantity pulmonary TB 7  
Quantity extra-pulmonary TB 7  
Quantity latent TB 3  
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Identification (NOK) 772 Reimbursement categories 701B+701C+701D+701G 
(Forskrift om utgifter til poliklinisk helsehjelp, 2013). 
Categories given by Oslo University Hospital. 
Quantity pulmonary TB 1  
Quantity extra-pulmonary TB 1  
Quantity latent TB 0 
 
 
 
 
Blood tests   
Costs of taking test (NOK) 96 Fee schedule category 701A (Norwegian Medical 
Association, 2013).  
   
Types of analyses   
CRP (NOK) 24 Reimbursement category 707B (Forskrift om utgifter 
til poliklinisk helsehjelp, 2013). Category given by 
Oslo University Hospital. 
Other types of analyses  (NOK) 72 Reimbursement category 704A*9 types of analyses 
(Forskrift om utgifter til poliklinisk helsehjelp, 2013). 
Category given by Oslo University Hospital. 
   
Total (NOK) 192   
Quantity pulmonary TB 1 One that is not covered by DRG for follow-up 
consultations 
Quantity extra-pulmonary TB 1 One that is not covered by DRG for follow-up 
consultations 
Quantity latent TB 1 One that is not covered by DRG for follow-up 
consultations 
   
Treatment plan meeting   
   
Length of meeting (minutes) 60 Expert opinion at NIPH. 
Wage, doctor (NOK) 565.2 (Statistics Norway, 2013) 
Wage, TB-coordinator (NOK) 318.8 (Statistics Norway, 2013) 
Wage, home services (NOK) 318.8 (Statistics Norway, 2013) 
Wage, community nurse (NOK) 318.8 (Statistics Norway, 2013) 
   
Total (NOK) 1521.5   
Quantity pulmonary TB 1  
Quantity extra-pulmonary TB 1  
Quantity latent TB 1  
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Hospitalization 
  
   
Value of one DRG point (NOK) 39447 (The Norwegian Directorate of Health, 2012a) 
Weight given for TB 2.696 DRG 79. Category given by the Norwegian 
Directorate of Health 
   
Total (NOK) 106349  39447*2.696 
Quantity pulmonary TB 1  
Quantity extra-pulmonary TB 0  
Quantity latent TB 0  
Follow-up consultations   
   
Value of one DRG point (NOK) 39447 (The Norwegian Directorate of Health, 2012a) 
Weight given for TB follow-up 0.043 DRG 904D. Category given by the Norwegian 
Directorate of Health 
   
Total (NOK) 1696   
Quantity pulmonary TB 4  
Quantity extra-pulmonary TB 4  
Quantity latent TB 2  
   
Nurse home visits   
   
Wage, weekday (per hour, NOK) 489 Personal communication UNICARE, Oslo 
Municipality 
Wage, weekend (per hour,NOK) 699 Personal communication UNICARE, Oslo 
Municipality 
Extra charge per visit (NOK) 56 Personal communication UNICARE, Oslo 
Municipality 
   
Esimated time spent per visit (minutes) 10 Personal communication UNICARE 
Weight given to weekday 5/7  
Weight given to weekend 2/7  
   
Total, one visit (NOK) 147.5 ((489*10 minutes)*5/7)+((699*10 minutes)*2/7)+56 
Quantity pulmonary TB 166  
Quantity extra-pulmonary TB 180  
Quantity latent TB 90 Only used in about 52% of treatments (see Table 1) 
   
Interpreter   
   
Hourly wage (NOK) 844 Average hourly wage paid by Oslo University Hospital 
Quantity pulmonary TB 8 Estimated based on number of patients and total hours 
used at Oslo University Hospital 
Quantity extra-pulmonary TB 8 Estimated based on number of patients and total hours 
used at Oslo University Hospital 
Quantity latent TB 2 Assumed 
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Medication   
   
Isoniazid+rifampicin (Rimactazid)   (Follow-up phase and LTBI) 
Maximum pharmacy purchase price 
(NOK) 
188.9 (Norwegian Medicines Agency, 2014b) 
Amount of tablets in box 60 (Norwegian Medicines Agency, 2014b) 
Amount of tablets to be taken each day 4 Assumed a person of 70kg weight. Amount of tablets 
per kilo taken from (NIPH, 2013). 
   
Cost per daily dose (NOK) 12.6 (188.9/60)*4 
   
Quantity pulmonary TB 120 (NIPH, 2013) 
Quantity extra-pulmonary TB 120 (NIPH, 2013) 
Quantity latent TB 90 (NIPH, 2013) 
   
Isoniazid+rifampicin+pyrazinamid+
ethambuthol (Rimstar)  
 (Intensive phase) 
Maximum pharmacy purchase price 478.4 (Norwegian Medicines Agency, 2014b) 
Amount of tablets in box 60 (Norwegian Medicines Agency, 2014b) 
Amount of tablets to be taken each day 4 Assumed a person of 70kg weight. Amount of tablets 
per kilo taken from (NIPH, 2013). 
   
Cost per daily dose 31.9 (478.4/60)*4 
   
Quantity pulmonary TB 46 (NIPH, 2013) 
Quantity extra-pulmonary TB 60 (NIPH, 2013) 
Quantity latent TB 0 (NIPH, 2013) 
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Appendix III: Cost-effectiveness plane 
Figure V Cost-effectiveness plane 
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Appendix IV: Alternative display of results 
Table II Results with a cohort of 10 000 
  osts (NOK) Avoided 
cases 
Active 
cases 
Incremental costs (NOK) Incremental avoided cases ICER (NOK) 
No screening 
47 557 157 0 399,9 Baseline Baseline Baseline 
IGRA risk 
47 747 209 8,0 391,9 190 051 7,9990 23 760 
TST+IGRA 
53 031 994 27,4 372,6 Extended dominance Extended dominance Extended dominance 
IGRA 
54 585 556 38,9 361,0 6 838 348 30,9417 221 008 
 
Table III Results when active cases are discounted at the same rate as costs (4%) 
  osts (NOK) Avoided 
cases 
Active 
cases 
Incremental costs (NOK) Incremental avoided cases ICER (NOK) 
No screening 4 756 0 0.0342 Baseline Baseline Baseline 
IGRA risk 4 775 0.0007 0.0335 19 0.0007 28 343 
TST+IGRA 5 303 0.0023 0.0319 Extended dominance Extended dominance Extended dominance 
IGRA 5 459 0.0033 0.0309 684 0.0026 265 110 
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Appendix V: Scenario analysis 
Table IV Results without costs of treatment of active TB 
  osts (NOK) Avoided 
cases 
Active 
cases 
Incremental costs (NOK) Incremental avoided cases ICER (NOK) 
No screening 621 0 0.0400 Baseline Baseline Baseline 
IGRA risk 721 0.0008 0.0392 100 0.0008 125 119 
TST+IGRA 1 445 0.0027 0.0373 Extended dominance Extended dominance Extended dominance 
IGRA 1 717 0.0039 0.0361 996 0.0031 321 858 
 
Table V Results when reactivation probabilities reduced in all groups (0.0025 and 0.0045 annual probability) 
  osts (NOK) Avoided 
cases 
Active 
cases 
Incremental costs (NOK) Incremental avoided cases ICER (NOK) 
No screening 1 974 0 0.0126 Baseline Baseline Baseline 
IGRA risk 2 058 0.0002 0.0125 84 0.0002 515 343 
TST+IGRA 2 722 0.0008 0.0119 Extended dominance Extended dominance Extended dominance 
IGRA 2 963 0.0011 0.0115 905 0.0009 975 299 
 
Table VI Results with secondary cases (0.2 per reactivated case) 
  osts (NOK) Avoided 
cases 
Active 
cases 
Incremental costs (NOK) Incremental avoided cases ICER (NOK) 
No screening 5 462 0 0.0470 Baseline Baseline Baseline 
IGRA risk 5 465 0.0010 0.0460 3 0.0010 2 906 
TST+IGRA 5 954 0.0033 0.0437 Extended dominance Extended dominance Extended dominance 
IGRA 6 086 0.0047 0.0423 621 0.0037 167 365 
 
Table VII Results when probability of group with risk factors being put on treatment is increased to 0.9 
  osts (NOK) Avoided 
cases 
Active 
cases 
Incremental costs (NOK) Incremental avoided cases ICER (NOK) 
No screening 4 756 0 0.0400 Baseline Baseline Baseline 
IGRA risk 4 700 0.0042 0.0358 -56 0.0042 -13 137 
TST+IGRA 5 251 0.0052 0.0348 Extended dominance Extended dominance Extended dominance 
IGRA 5 384 0.0073 0.0327 684 0.0031 221 008 
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Appendix VI: One-way sensitivity analysis for 
probabilities 
Table VIII Several one-way analyses for probabilities, with and without extendedly dominated (ED) strategies. 
ICERs are relative to the strategy to its left. IGRA risk is compared to no-screening (not shown).  
Kolonne1 Base 
esimate 
Values 
explored 
IGRA risk 
(ICER) 
TST+IGRA 
(ICER) 
IGRA 
(ICER) 
Probability IGRA-positive (both groups) 0.29 0.1 109 951 ED 435 096 
    0.2 44 110 ED 271 556 
    0.3 22163 ED 217 043 
    0.4 11 190 ED 189 787 
    0.5 4606 ED 173 433 
Extendedly dominated strategy included   0.1 109 951 508 850 311 511 
    0.2 44 110 328 479 176 174 
    0.3 22 163 268 356 131 062 
    0.4 11 190 238 294 108 506 
    0.5 4 606 220 257 94 972 
Probability IGRA-positive, high risk group 0.29 0.29 23760 ED 221 008 
    0.39 12034 ED 221 008 
    0.49 5 143 ED 221 008 
    0.59 589 ED 221 008 
    0.69 -2646 ED 221 008 
Extendedly dominated strategy included  0.29 23 677 272 798 134 278 
    0.39 12 034 286 608 122 772 
    0.49 5 143 301 697 112 696 
    0.59 589 318 250 103 798 
    0.69 -2 646 336 491 95 884 
Probability of having risk factors 0.09 0.05 25 654 ED 221 008 
    0.1 23 501 ED 221 008 
    0.15 22 783 ED 221 008 
    0.2 22 424 ED 221 008 
    0.25 22 208 ED 221 008 
Extendedly dominated strategy included  0.05 25 654 258 151 148 320 
    0.1 23 501 277 248 130 790 
    0.15 22 783 302 276 115 558 
    0.2 22 424 336 505 102 199 
    0.25 22 208 386 151 90 388 
Probability treated (both groups) 0.17 0.1 55 610 ED 300 121 
    0.3 4 050 ED 172 052 
    0.5 -6 262 ED 146 438 
    0.7 -10 682 ED 135 460 
    0.9 -13 137 ED 129 362 
Extendedly dominated strategy included  0.1 55 610 376 918 171 436 
    0.3 4 050 208 254 111 389 
    0.5 -6 262 174 521 99 379 
    0.7 -10 682 160 064 94 232 
    0.9 -13 137 152 033 91 373 
Probability treated, high risk group 0.17 0.1 55 610 ED 221 008 
    0.3 4 050 ED 221 008 
    0.5 -6 262 ED 221 008 
    0.7 -10 682 ED 221 008 
    0.9 -13 137 ED 221 008 
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Extendedly dominated strategy included  0.1 55 610 258 577 148 766 
    0.3 4 050 303 179 113 159 
    0.5 -6 262 364 662 89 855 
    0.7 -10 682 454 843 73 417 
    0.9 -13 137 599 937 61 201 
Probability of completing treatment 0.84 0.5 96 608 ED 407 763 
    0.6 66 710 ED 331 116 
    0.7 45 354 ED 276 369 
    0.8 29 338 ED 235 308 
    0.9 16 880 ED 203 372 
Extendedly dominated strategy included  0.5 96 608 492 278 266 145 
    0.6 66 710 402 172 212 052 
    0.7 45 354 337 811 173 414 
    0.8 29 338 289 540 144 435 
    0.9 16 880 251 995 121 896 
Annual reactivation probability, low risk group 0.011 0.0025 23 760 ED 1 312 588 
    0.0075 23 760 ED 378 344 
    0.0125 23 760 ED 191 463 
    0.0175 23 760 ED 111 348 
    0.0225 23 760 ED 66 822 
Extendedly dominated strategy included  0.0025 23 760 2 706 764 507 961 
    0.0075 23 760 490 777 217 384 
    0.0125 23 760 234 666 116 852 
    0.0175 23 760 135 592 65 851 
    0.0225 23 760 82 999 35 000 
Annual reactivation probability, high risk group 0.032 0.0035 ED ED 242 603 
    0.0045 ED ED 239 693 
    0.0075 ED ED 231 363 
    0.0100 ED ED 224 845 
    0.0200 89 989 ED 221 008 
Extendedly dominated strategy included  0.0035 932 123 236 336 186 289 
    0.0045 705 313 237 612 183 857 
    0.0075 387 765 241 448 176 892 
    0.0100 268 674 244 652 171 442 
    0.0200 89 989 257 521 152 369 
Decline in annual reactivation probability 0.081 0 -1 030 ED 148 401 
    0.05 13 747 ED 191 734 
    0.1 30 237 ED 239 913 
    0.15 48 201 ED 292 226 
    0.2 67 300 ED 347 661 
Extendedly dominated strategy included  0 -1 030 187 341 82 684 
    0.05 13 747 238 303 113 509 
    0.1 30 237 294 960 147 801 
    0.15 48 201 356 472 185 058 
    0.2 67 300 421 647 224 562 
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The following strategies only affected the ICERs when the extendedly dominated strategy was included, hence these are only shown 
including that strategy. 
 Base 
esimate 
Values 
explored 
IGRA risk 
(ICER) 
TST+IGRA 
(ICER) 
IGRA 
(ICER) 
Probability of being missing following 
TST 
0.2 0 23 760 237 556 129 077 
    0.1 23 760 252 502 132 816 
    0.2 23 760 272 728 134 343 
    0.3 23 760 301 630 135 172 
    0.4 23 760 346 314 135 693 
Probability TST positive, 0.88 0.6 23 760 404 972 123 866 
given (underlying) IGRA positive   0.7 23 760 338 402 126 402 
    0.8 23 760 296 342 130 066 
    0.9 23 760 267 359 135 823 
    1 23 760 246 175 146 186 
Probability TST positive,   0.35 0 23 760 233 087 200 767 
given (underlying) IGRA negative   0.15 23 760 249 987 172 449 
    0.3 23 760 266 886 144 131 
    0.45 23 760 283 786 115 814 
    0.6 23 760 300 685 87 496 
 
74 
 
Appendix VII: One-way sensitivity analysis for costs 
Table IX Several one-way analyses for costs, with and without the extendedly dominated (ED) strategies 
included.  
Kolonne1 Base esimate Values explored IGRA risk (ICER) TST+IGRA (ICER) IGRA (ICER) 
Cost, treatment of active TB 120 946 75 000 62 265 ED 259 319 
  125 000 20 362 ED 217 627 
  175 000 -21 541 ED 175 935 
  225 000 -63 444 ED 134 242 
  275 000 -105 346 ED 92 550 
Extendedly dominated strategy included 120 946 75 000 62 265 311 016 172 694 
  125 000 20 362 269 350 130 958 
  175 000 -21 541 227 683 89 223 
  225 000 -63 444 186 017 47 487 
  275 000 -105 346 144 350 5 752 
Cost, treatment of latent TB 15 133 5 000 -31 897 ED 75 021 
  10 000 -4 435 ED 147 053 
  15 000 23 027 ED 219 086 
  20 000 50 489 ED 291 118 
  25 000 77 951 ED 363 151 
Extendedly dominated strategy included 15 133 5 000 -31 897 115 668 6 911 
  10 000 -4 435 193 164 69 788 
  15 000 23 027 270 661 132 665 
  20 000 50 489 348 157 195 542 
  25 000 77 951 425 653 258 419 
Cost, IGRA 386 300 13 624 ED 195 834 
  350 19 517 ED 210 470 
  400 25 409 ED 225 106 
  450 31 302 ED 239 742 
  500 37 194 ED 254 378 
 386 300 13 624 258 871 90 205 
  350 19 517 266 928 115 866 
  400 25 409 274 984 141 528 
  450 31 302 283 040 167 189 
  500 37 194 291 097 192 851 
Cost, TST 168 100 23 760 ED 221 008 
  175 23 760 ED 221 008 
  250 23 760 ED 221 008 
  325 23 760 ED 221 008 
  400 23 760 ED 221 008 
Extendedly dominated strategy included 168 100 23 760 237 724 192 998 
  175 23 760 276 428 128 142 
  250 23 760 315 133 63 287 
  325 23 760 353 838 -1 568 
  400 23 760 392 542 -66 424 
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Appendix VIII: EVPPI 
Figure VI Showing results of EVPPI for a cohort of 16 000 at a WTP-threshold of 222 000 NOK.  
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Figure VII Figure showing the results of EVPPI at a threshold of 24 000 NOK per screened individual. 
Figure VIII Figure showing results of EVPPI at a threshold of 24 000 NOK for a cohort of 16 000 
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